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Transmembrane signaling through Gαq-coupled receptors is linked to 
physiological processes such as cardiovascular development and smooth muscle 
function.  Crystallographic studies have shown that Gαq forms an effector like 
interaction with G protein-coupled receptor kinase 2 (GRK2) in a manner that 
does not appear to sterically overlap with the binding site for regulators of G 
protein signaling (RGS) proteins.  We confirm the formation of higher order RGS-
Gαq-effector complexes using a flow cytometry protein interaction assay (FCPIA).  
Our data further supports the notion that GRK2 is a bona fide effector of Gαq. 
 
Indeed, protein interactions involving GRK2 have become increasingly complex.   
There is growing evidence that GRK2 phosphorylates many non-GPCR 
substrates, some of which are in response to activation of Gαq-coupled 
receptors.  Small molecule inhibitors that could specifically inhibit the binding of 
Gαq to GRK2 would serve as powerful pharmacological tools that could be used 
to better understand the full significance of this interaction.  We developed a 
high-throughput screening assay using FCPIA to identify small molecule 
inhibitors of the Gαq-GRK2 interaction.  While our initial screening efforts failed to 
yield any discernable lead compounds, modifications of our assay could be used 
 
 xx 
to screen additional chemical libraries that are better designed towards inhibiting 
protein-protein interactions.  
 
The canonical role of GRK2 is to phosphorylate the cytoplasmic tails/loops of 
activated G protein-coupled receptors (GPCRs).  Phosphorylated receptors can 
then be uncoupled from G proteins, thereby desensitizing the signaling pathway.  
Since the discovery of a linkage between the over-expression of GRK2 and heart 
failure, GRK2 has become a pharmaceutical target for the treatment of heart 
disease.  Takeda Pharmaceuticals have discovered a class of selective GRK2 
inhibitors.  We have solved the crystal structures of two of these compounds 
bound to GRK2-Gβγ.  Our crystal structures reveal that these compounds bind to 
an inactive kinase conformation, in a manner similar to the cancer drug imatinib. 
Recently, an RNA aptamer has been discovered that is also capable of 
selectively inhibiting GRK2.  Crystallographic data indicates that the aptamer 
stabilizes an inactive conformation similar to that recognized by the Takeda 
compounds.  We have developed an aptamer displacement assay using FCPIA 
that is currently in use to screen for small molecule inhibitors that bind to this 





Chapter 1  
General Introduction 
 
G Protein-Coupled Receptor Signaling 
Cell to cell communication is an essential process for all forms of life.  Signal 
transduction is the cellular mechanism whereby environmental stimuli are 
converted into specific cellular responses.  At the hub of signal transduction 
pathways are cell surface receptors, which receive extracellular signals (such as 
light, odors, hormones, etc.) as an input and output intracellular signals that 
affect physiological processes ranging from vision, taste, and smell to 
neurotransmission, blood pressure, and immune response.  One class of cell-
surface receptors is the G protein-coupled receptors (GPCRs), which are a family 
of integral membrane proteins that contain seven-transmembrane spanning 
helices.  GPCRs are involved in a wide variety of both physiological and 
pathophysiological processes.  They are a major pharmaceutical target and 
account for 30-60% of all modern drugs (1-4).  
 
GPCRs constitute the largest superfamily of cell surface receptors and are 
comprised of over 800 genes (~4% of total human genes) (5). They are only 
found in eukaryotes, and are present in yeast, plants, protozoa, and metazoa (1).  
Structurally, GPCRs can be characterized by an extracellular N-terminus, 
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followed by seven transmembrane α-helices that form three intracellular loops 
and three extracellular loops, and an intracellular C-terminus (6).  The GPCR 
superfamily has classically been divided into three main families (A, B, and C) 
based on protein sequence similarity (7).  Family A is the largest member 
accounting for approximately 90% of all GPCRs with rhodopsin being the 
prototypical member.  A characteristic feature of family A GPCRs is a conserved 
DRY sequence motif in the cytoplasmic end of 3rd transmembrane domain, which 
plays an important role in regulating conformational states (8). 
 
GPCRs are given their name for their ability to activate heterotrimeric GTP-
binding proteins (G proteins), which are composed of α, β, and γ subunits.  G 
proteins serve as molecular switches by coupling the activation of a receptor to 
an intracellular response.  In the inactive state, G proteins form a heterotrimer 
where Gα binds GDP and a constitutive Gβγ heterodimer.  Upon receptor 
activation, GPCRs act as guanine-nucleotide exchange factors (GEFs) and 
promote the dissociation of GDP from the Gα subunit, allowing GTP to bind, and 
causing dissociation of the Gα-GTP and Gβγ subunits (Figure 1).  Activated Gα-
GTP and free Gβγ subunits are then able to bind their respective effector 
molecules and initiate downstream signaling pathways such as the cyclic 
adenosine monophosphate (cAMP) pathway and the phosphotidylinositol 
pathway (9).  The signaling pathway is terminated when the Gα subunit 
hydrolyzes GTP to GDP, causing the reassociation of Gα-GDP and Gβγ into the 
inactive heterotrimeric G protein.  The termination process can be accelerated by 
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GTPase activating proteins (GAPs) such as regulator of G protein signaling 
(RGS) proteins, which enhance the intrinsic GTPase activity of most Gα subunits 
(4, 10-12).   
 
Figure 1: Canonical GPCR signaling pathway.  Upon agonist binding, the 
GPCR becomes activated and catalyzes the exchange of GTP for GDP on the 
Gα subunit, activating both the Gα and Gβγ subunits.  Gα-GTP and Gβγ are then 
free to bind and activate their respective effector molecules, which then generate 
second messenger molecules and continue the signaling cascade.  Signaling is 
terminated when GTP is hydrolyzed to GDP by intrinsic GTPase activity of the 




In addition to activating G proteins, the activation of GPCRs triggers their 
phosphorylation by G protein-coupled receptor kinases (GRKs).  In a process 
termed homologous desensitization, phosphorylated receptors are bound by a 
family of proteins called arrestins that block coupling with heterotrimeric G 
proteins.  Arrestins can also induce receptor downregulation by coupling 
phosphorylated receptors to the endocytic machinery to internalize receptors (13-
15).  
 
Structure and Function of Heterotrimeric G proteins 
Whereas there are over 800 GPCRs, there are relatively few heterotrimeric G 
proteins.  There are 21 Gα subunits (encoded by 16 genes), five Gβ subunits, 
and 12 Gγ subunits.  Gα proteins are divided into four main classes based on 
primary sequence identity between the Gα subunits: Gαs, Gαi, Gαq, and Gα12/13 
(11).  In the active, GTP-bound state, Gα subunits bind and activate specific 
effector proteins, with each class of Gα subunits traditionally linked to one or 
more specific effector proteins.  For example, activated Gαs stimulates adenylyl 
cyclase (AC) resulting in an increase of the second messenger cAMP, whereas 
activated Gαi inhibits production of cAMP from AC.  Activated Gαq activates 
phospholipase C-β (PLCβ) which cleaves the phospholipid phosphatidylinositol 
4,5-bisphosphate (PIP2) into diacyl glycerol (DAG) and inositol 1,4,5-triphosphate 
(IP3).  Gα12/13 subunits activate Rho guanine nucleotide exchange factors 
(RhoGEFs) which further activate small GTPases such as RhoA.  Furthermore, 
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free Gβγ subunits can activate a number of effectors such as PLCβs, ACs, 
phosphitidylinositide 3-kinase  (PI3K), inwardly rectifying potassium channels, 
and voltage-gated calcium channels (11, 16).  
 
The Gα Subunit 
Structurally, Gα subunits are composed of two domains: a GTPase domain 
involved with the binding and hydrolysis of GTP, and an α-helical domain that 
forms a lid over the nucleotide binding site (Figure 2).  The GTPase domain 
belongs to the Ras GTPase superfamily and is composed of a six-stranded β-
sheet surrounded by five α-helices.  The most highly conserved sequences in 
this domain are those used in guanine nucleotide binding: the diphosphate (P) 
loop (GXGESGKS), the Mg2+binding loops (RXXTXGI and DXXG), and the 
guanine nucleotide binding motifs (NKXD and TCAT).  This domain is typically 
known for the three flexible loops near the γ-phosphate binding site termed 
switches I, II, and III, which show significant structural differences between the 
GDP- and GTP-bound forms (Figure 2A).  Switch I contains the Mg2+ binding 
loop, which participates in GTP hydrolysis along with the P loop, and its structure 
is only slightly affected by GTP hydrolysis or effector/regulator protein binding.  
Switch II also contributes to the hydrolysis of GTP, and forms part of the binding 
pocket for the γ-phosphate from GTP.  Upon GTP hydrolysis switch II transitions 
from a more ordered to a less ordered conformation (Figure 2B).  Switch III is a 
loop that contacts switch II through ionic and polar interactions in the GTP-bound 
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state.  Overall, the loss of stability in switches II due the GDP bound state is 
responsible for the change in affinity of Gα subunits for effectors (16-18).   
 
 
Figure 2:  Crystal structures of Gα12/13 in the deactivated and activated 
states. The secondary structural elements for the α-helical domain are labeled 
with letters (e.g. αA) and the GTPase domain are labeled with numbers (e.g. α1 
and β2).  The three flexible switch regions that undergo a conformational change 
upon nucleotide exchange are colored in red.  The GDP and Mg2+·GDP·AlF4- 
ligands bind in the active site and are shown as a ball and stick models with 
carbons colored green, nitrogens blue, oxygens red, phosphates orange, 
aluminum peach, fluorines white, and magnesium black.  A) The inactive 
Gαi/13·GDP complex (PDB:1ZCB) in a open conformation.  Switch II is completely 
disordered and switch III is rotated away from the nucleotide-binding site.  B) The 
activated Gαi/12·GDP·AlF4- complex (PDB:1ZCA) in a closed conformation.  
Switch II is now ordered and switch III is closer to the nucleotide-binding site, 
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thus forming an interface between the α2 and α3 helices that bracket the 
effector-binding site. 
 
The Gβγ Subunits 
The G protein β and γ subunits form a constitutive dimer that cannot be 
dissociated except by denaturation.  Gβ has a seven-bladed β-propeller structure 
that is formed by seven WD40 repeats, with each repeat being composed of four 
antiparallel β-strands.  The Gβ subunit interacts with both the switch I and II 
regions of the GDP-bound Gα subunit and the N-terminal helix of the Gα subunit.  
The Gγ subunit is small protein (~8 kDa) consisting of two α-helices that form a 
coiled coil with the N terminal helical segment of Gβ.  All Gγ subunits undergo a 
posttranslational lipid modification at their C-termini consisting of either a 15-
carbon farnesyl or 20-carbon geranylgeranyl group (11).   
 
Gαq Signaling and its Physiological Roles 
The heterotrimeric G protein Gq is a key regulator of cardiovascular development 
and function (20).  Approximately 40% of all GPCRs couple to the Gq family of 
Gα subunits, which consists of four members: Gαq, Gα11, Gα14, and Gα15/16.  The 
canonical effectors for all Gq family members are the β-isoforms of PLC, which 
hydrolyze PIP2 into IP3 and DAG (19).  These second messengers propagate 
and amplify the Gq-mediated signal by releasing intracellular stores of calcium 
and activating protein kinase C (PKC).  Together, inosititol lipids, DAG, PKC, and 
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calcium are able participate in multiple signaling networks linking Gq-coupled 
receptors to a wide range of physiological functions such as cell growth and 
proliferation, platelet aggregation (20), neuronal signaling, glucose secretion, 
actin cytoskeleton reorganization (21), and smooth muscle contraction (19, 22, 
23).  
 
In addition to interacting with PLCβ, Gq family members interact with a myriad of 
other binding partners.  In particular, activated Gαq has been show to bind to the 
guanine nucleotide exchange factor, p63RhoGEF (24), which activates the small 
G protein RhoA.  Furthermore, activated Gαq has been shown to bind to: G 
protein coupled receptor kinase 2 (GRK2 (25-28) and GRK3 (29)), non-receptor 
guanine nucleotide exchange factor Ric-8A (30, 31), tubulin (32, 33), caveolin-1 
(34), non-receptor tyrosine kinase Btk (35), and the p110α subunit of PI3K (36).  
Thus, overall signaling through Gαq is fairly complex, as one might expect for a 
protein that is involved in such a wide range of physiological functions. 
 
While all Gq family members share the common effector PLCβ, they are not 
functionally redundant, and differ in tissue expression, amino acid sequence 
identity, downstream binding partners, and ultimately cell physiology.  Gαq and 
Gα11 are ubiquitously expressed and have a 90% amino acid sequence identity.  
Gα14 is expressed in the kidney, liver, and lung, and is 80% similar in amino acid 
sequence identity with respect to Gαq, and Gα15/16 is found only in tissues rich in 
hematopoietic cells, where it plays an important role in erythroid differentiation 
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and T-cell activation.  Both Gαq and Gα11 are dually palmitoylated at cysteines 
Cys9 and Cys10, which has been shown to be important for membrane 
attachment and interactions with proteins and lipids.  Furthermore, the N-terminal 
region is highly positively charged and contains contact residues for Gβγ 
subunits, making the N-terminal region critical for G protein function (19).  
 
Genetic studies of Gαq have heavily implicated Gαq signaling in the development 
of heart failure (19, 37).  Double homozygous null mutations for Gαq and Gα11 
induce cardiomyocyte hypoplasia and embryonic lethality, while mice with one 
intact allele of either gene die shortly after birth due to cardiac defects (38).  
Selective disruption of Gαq impairs platelet function and increases bleeding times 
in mice (20, 39).  Further studies with transgenic cardiomyocyte lines prove that 
Gαq is essential for cardiomyocyte hypertrophy and proliferation during 
development, and link Gαq signaling to cardiac hypertrophy and heart failure in 
adults (38, 40).  Additionally, loss of Gαq affects neuronal cerebellar activity (41) 
and impairs lung function in response to allergens (42).  In contrast to Gαq, mice 
genetically deficient in Gα11, Gα14, and Gα15 show normal growth characteristics, 
but have signaling deficiencies (38).  For example, in erythroleukemia cells loss 
of Gα16 completely blocks calcium signaling by the purinergic receptor P2Y2 (43).  
Overall current studies indicate differing roles for the Gq family members with Gαq 
playing a more prominent physiological role. Understanding the many 
interactions of Gαq with respect to receptors, effectors, and regulators will 
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ultimately shed light onto how Gαq signaling can give a specific cellular response 
that is both dependent and independent of inositol lipid signaling. 
 
Regulation of Gαq Signaling 
Intrinsic GTPase Activity  
G protein signaling is terminated upon hydrolysis of GTP to GDP with Gα 
reassociating with Gβγ and forming the inactive heterotrimeric G protein.  Our 
current understanding of the mechanism of GTP hydrolysis has come from a 
series of crystal structures of the Gα subunit bound to GDP (44, 45), GDP·Pi (46, 
47), GTPγS (48, 49) and GDP·AlF4- (49, 50).  Aluminum fluoride is a strong 
activator of Gα subunits, and in the GDP·AlF4- crystal structure the AlF4- ion is in 
a square planar configuration with the oxygen of the β-phosphate and a water 
molecule occupying axial positions.  Therefore, this ligand mimics the transition-
state of GTP hydrolysis.  Biochemical and structural studies implicated Arg 178 
and Gln 204 (Gαi, Figure 3B) as the catalytic residues of GTP hydrolysis.  The 
glutamine residue coordinates and polarizes the catalytic water molecule, and 
the arginine stabilizes the developing negative charge on the transition state (11, 
17). 
 
Regulators of G protein Signaling (RGS) Proteins 
Initially it was thought that the GTP hydrolysis was an unregulated function of the 
Gα subunits (51).  However, in the visual cycle the physiological half-lives (~100 
ms) were much faster than the in vitro half-lives for GTP hydrolysis (~15 s).  
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Soon after it was discovered that GTPase activating proteins (GAPs) accelerate 
the catalytic rate of GTP hydrolysis (12).  The first discovered GAP for Gα 
subunits was the Gαq effector PLCβ, which could accelerate GTP hydrolysis by 
more than 50-fold (52).  More recently, another class of was discovered: the 
regulator of G protein signaling (RGS) proteins (53-55). 
 
RGS proteins can be classified into four families based on sequence homology: 
R4, R7, R12, and RZ, with R4 being the largest family with nine members (56).  
All RGS proteins share a conserved ~120 amino acid RGS homology (RH) 
domain that accelerates GTP hydrolysis.  While some RGS proteins contain little 
more than the RH domain (as is common in the R4 family), others have 
additional domains that are able to regulate RGS activity (57). 
 
There are now over seven crystal structures of Gα subunits in complex with RGS 
proteins (58).  In each of these structures, the Gα subunit is activated by the non-
natural substrate GDP·AlF4-, and the RGS proteins do not donate any catalytic 
residues to the active site, unlike the Ras GAPs, which contribute an “arginine 
finger” to promote hydrolysis. Instead, the available evidence indicates that RGS 
proteins accelerate GTP hydrolysis by stabilizing the transition state of GTP 
hydrolysis (16, 59).  
 
Structurally, there are two important interactions formed between RGS proteins 
and Gα subunits.  Using RGS4-Gαi1 as an example (Figure 3), the residue Gαi1-
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Thr182 in switch I rotates 120° to make contacts with RGS4-Asn88, allowing for 
the formation of a hydrogen bond network involving Thr182 and the switch II 
residues Glu207 and Lys210, which does not occur in the absence of RGS 
protein.  The second key interaction is formed by RGS4-Asn128, which packs 
against both switch I and II, directing the catalytic glutamine (Gln204) to 
coordinate the catalytic water and γ-phosphate during the transition state (11, 16, 
58).  Mutation of this residue or its equivalents in other RGS proteins can greatly 
inhibit GAP activity, as in RGS4-N128A (60) and RGS2-N149D (61).   
 
In general, the structural differences between the different Gα-RGS interfaces 
are subtle.  However, several RGS proteins exhibit selectivity towards different 
Gα subunits.  For example, RGS4 can serve as a GAP for both Gαi and Gαq 
(62), but RGS2 has been shown to be selective towards Gαq (63, 64).  Selectivity 
between the major Gα classes is likely mediated by differences in the RH 
domain-switch I/II interface, whereas differences in the RH domain-switch III 
interface could play a role in selectivity among Gα family members (58).  It is 
interesting to speculate if effector binding could modify RGS selectivity towards 






Figure 3: RGS4 binds to the three switch regions of Gα i. A) Structure of 
Gαi1·GDP·ALF4- in complex with RGS4.  Gαi is colored green and RGS4 is 
colored blue.  The switch regions of Gαi are colored red.  RGS4 makes contacts 
with all three switch regions of Gαi stabilizing the transition state of GTP 
hydrolysis.  B)  A close-up view of the Gαi-RGS4 interface with GTPγS modeled 
from the Gαi·GTPγS structure (PDB:1GIA) in place of GDP·AlF4-.  RGS4 does not 
directly take part in the catalysis of GTP hydrolysis. 
 
G protein-coupled Receptor Kinase 2 (GRK2) 
G protein-coupled receptor kinases (GRKs) are members of the protein kinase A 
(PKA), G, and C (AGC) family of kinases that phosphorylate serine/threonine 
residues on the third cytoplasmic loop or carboxyl terminal tail of agonist bound 
GPCRs (65).  Receptor phosphorylation promotes the binding of arrestin, which 
uncouples receptors from G proteins and targets them for endocytosis (13, 15).  
There are seven mammalian GRKs that are classified into three subfamilies 
based on their gene structure and homology: GRK1 (GRK1 and -7), GRK2 
(GRK2 and -3), and GRK4 (GRK4-6).  All GRKs have a similar overall structure 
with a N-terminal RH domain, a central catalytic kinase domain, and a less 
conserved C terminal domain that is typically involved in targeting the kinases to 
the plasma membrane.  For example, the GRK2 family contains a pleckstrin 
homology (PH) domain in the C-terminus that binds free Gβγ subunits, resulting 




In addition to inhibiting GPCR function via phosphorylation, GRK2 has been 
shown to inhibit signaling via a phosphorylation independent mechanism on 
numerous Gαq-coupled receptors including: the angiotension II receptor (67), the 
endothelin A and B receptors (68), the thromboxane A2 receptor (29), the 
parathyroid hormone receptor (PTH) (69), the M1 muscarinic acetylcholine 
receptor (M1AChR) (70), and the metabotropic glutamate 1a receptor  (71).  The 
mechanism of the phosphorylation independent densensitization was attributed 
to the N-terminal RH domain of GRK2, both biochemically and structurally (25, 
26, 29).  Initial studies showed that activated Gαq could bind GRK2 (and GRK3), 
and that overexpression on the N-terminal RH domain was sufficient to attenuate 
signaling through Gαq.  Furthermore, a kinase deficient mutant of GRK2 (K220R) 
was capable of desensitizing Gαq-coupled receptors (72).   
 
Although one might initially expect GRK2 to regulate Gαq activity by acting as a 
GAP, given its RH domain, GRK2 has little or no GAP activity (29, 73). 
Additionally, mutagenesis studies showed that GRK2 has two unique residues 
(Arg106 and Asp110) that are required for Gαq binding, which are not in 
equivalent positions used by RGS proteins to bind Gα subunits (74, 75). The 
crystal structure of the Gαq-GRK2-Gβγ complex (Figure 4C) (26) revealed that 
GRK2 binds Gαq much like an effector, as seen in the structures of Gαs-AC 
(Figure 4A) (76), Gαt-PDEγ-RGS9 (77), Gα13-p115RhoGEF  (78), and the more 
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Figure 4: Gα-effector complexes.  All Gα subunits are colored in green with the 
switch regions in red.  A) Gαs·GTPγS in complex with the VC1 and IIC2 subunits 
of adenylyl cyclase, respectively colored cyan and orange (PDB: 1CJT).  B) 
Gαi/q·GDP·AlF4- in complex with residues 343-490 of p63RhoGEF colored in 
violet (PDB: 2RGN).  C) Gαi/q·GDP·AlF4- in complex with residues 97-141 of 
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GRK2 colored blue (PDB: 2BCJ).  D) A close-up view of panels (A-C) overlaid 
onto the surface of Gαs·GTPγS (colored in green).  Adenylyl cyclase, 
p63RhoGEF, and GRK2 make extensive contacts with the switch II and α3 
helices of Gα subunits. 
 
Evidence for High Order Gαq Signaling Complexes 
An important question in cellular signaling is what determines the specificity of 
the signal transduction process.  The collision-coupling model (79) suggests that 
the signaling specificity is solely determined by the structure of the receptor-G 
protein interaction and the G protein-effector interface.  Additionally, the model 
depicts the individual membrane proteins as being freely dissolved, thus, 
activated proteins will freely diffuse throughout the membrane until they randomly 
collide with their target.   
 
A major inconsistency in the collision-coupling model is how do activated 
proteins, such as Gβγ, maintain their signaling specificity within a cell.  For 
example, in cardiomyocytes activation of the β2-adrenergic receptor (β2AR) 
causes Gαs-mediated activation of AC.  However, in the same cells, the inwardly 
rectifying potassium channel (Kir 3) is opened by Gβγ in response to activation of 
Gαi by the M2-muscuranic receptor (80).  Thus, according to the collision-
coupling model free Gβγ from the activation of β2AR would also be able to open 
Kir 3 channels, which does not normally happen in cells, indicating that specificity 
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is controlled.  In this case, specificity could be controlled by pre-formed 
complexes between receptor, G protein, and effector, preventing cross-talk into 
another pathway (81).  Signaling complexes can also combine multiple activities 
allowing for more efficient control of steady state levels of signaling.  Kinetic data 
shows that Gαq, PLCβ1, and the M1AChR can exist in an activated complex 
where the GEF activity of the receptor and the GAP activity of PLCβ1 can 
achieve any physiological rate of activity, without the need of other regulatory 
proteins (82).  There is further evidence that RGS proteins can play a role in this 
complex by acting as a “kinetic-scaffold” that limits the range of G protein signals 
(83).  
 
Figure 5: Model of a high order complex with a Gα subunit, effector, and 
RGS protein.  Gαt/i·GDP·AlF4- (green) in complex with PDEγ (magenta) and 
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RGS9 (blue) (PDB: 1FQJ).  Formation of the ternary complex is required to 
achieve physiological rates of GTP hydrolysis on Gαt. 
 
Additional evidence exists for high order signaling complexes given the crystal 
structures of the Gαi-RGS4 (59) and Gαs-adenylyl cyclase (76) complexes, which 
revealed that RGS proteins and effectors interact with discrete footprints on the 
surface of Gα and have the potential to bind simultaneously, although Gαs is not 
known to be regulated by RGS proteins.  Direct experimental support for an 
RGS-Gα-effector ternary complex came from analysis of the interactions of 
transducin (Gαt) with RGS proteins and the γ subunit of cGMP 
phosphodiesterase (PDEγ).  Both PDEγ (52) and RGS9 (84) are required for 
physiological rates of GTP hydrolysis on Gαt.  Although PDEγ has no GAP 
activity on its own, it can stimulate RGS9-mediated GAP activity by up to ~3 fold 
(84).  Mutagenesis studies (85), biophysical measurements (86), and ultimately 
the crystal structure of the RGS9-Gαt/i1-PDEγ ternary complex (Figure 5) (77) 
were all consistent with a model of allosteric modulation between the effector and 
RGS-binding sites of Gαt, with little or no direct functional interaction between 
PDEγ and RGS9.  It has been proposed that this PDEγ-regulated GAP activity 
prevents a “short-circuit” of the phototransduction cascade via premature 
hydrolysis of Gαt·GTP before effectors can functionally interact with the G protein 
(87).  Conversely, PDEγ inhibits the GAP activity of other RGS proteins (RGS4, 
GAIP and RGS16/RGSr), most likely through a negative allosteric mechanism 
(87-89), supporting the conclusion that RGS9 and Gαt represent a physiologically 
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relevant pair.  It is not known whether similar ternary complexes are formed by 
other members of the Gαi family or by subunits from the Gαq family, or if there 
are other effector/RGS combinations that are synergistic with respect to GAP 




Chapter 2  
 Assembly of High Order Gαq-Effector Signaling Complexes 
 with RGS Proteins 
 
BACKGROUND AND RESEARCH PLAN 
The crystal structure of the Gαq-GRK2-Gβγ complex revealed that GRK2 binds to 
the effector-binding site of Gαq (26), raising the interesting possibility that GRK2 
is in fact an effector that can initiate its own signaling cascades in response to 
the activation of Gαq.  Although one obvious pathway is simply the 
phosphorylation of activated GPCRs, GRK2 has also recently been shown to 
phosphorylate insulin receptor substrate-1 (IRS-1) (90), p38 MAP kinase (91), 
and ezrin (92) in response to GPCR activation.  Additionally, the binding of GRK2 
to Gαq is such that it leaves the RGS binding site accessible.  This leads to the 
question of whether or not GRK2 and RGS proteins can form ternary complexes 
with Gαq.  
 
The rate of GTP hydrolysis by Gαq can be accelerated by many different RGS 
proteins (19), but two of the best characterized are RGS2 and RGS4, which are 
both members of the RGS B/R4 subfamily (93, 94).  Both proteins have been 
reported to serve as effector antagonists because they can inhibit PLCβ signaling 
by either GTPase-deficient Gα subunits or Gα subunits loaded with non-




In this project, we have used biophysical and kinetic studies to demonstrate the 
formation of ternary complexes of between Gαq, RGS2/4 and the effectors 
GRK2/p63RhoGEF.  We also showed that RGS2 and RGS4 are negative 
allosteric modulators of proteins that bind to the effector-binding site of Gαq, 
providing a probable molecular basis for their roles as effector antagonists.  
Conversely, GRK2 and p63RhoGEF are shown to be allosteric modulators of 
RGS GAP activity.  Interestingly, GRK2 stimulates RGS4 GAP activity on Gαq to 
an extent that is similar to that of PDEγ on RGS9-Gαt.  These data provide novel 
insights into the possible mechanisms of regulation of GRK2 and p63RhoGEF by 
both Gαq and RGS proteins in vivo. 
METHODS 
Purification of RGS2 and RGS4.   
Human RGS2 (1-211), ΔN-RGS2(72-211), RGS2(1-72), and RGS2-N149D were 
cloned into the pMALc2H10T vector using the BamHI and SalI restriction sites 
and expressed as as a maltose-binding protein (MBP) fusion protein in Rosetta 
(DE3) pLys cells (97).  Bacterial cells were grown to an OD600 of 0.8 and 
expression of RGS2 was inducted by the addition of 100ug/mL of 
isopropylthiogalactopyranoside (IPTG) at 20° C. The cells were harvested after 
20 hours by centrifugation and frozen in liquid nitrogen.  Cell pellets were 
resuspended in lysis buffer (20 mM HEPES pH 8.0, 500 mM NaCl, 10 mM β-
mercaptoethanol) plus 1 µM leupeptin, 1 mM lima bean trypsin inhibitor and 0.1 
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mM phenylmethylsulphonyl fluoride.  Cells were lysed with an Avestin C3 
homogenizer and ultracentrifuged at 40,000 rpm for 1 hr using a Beckman Type 
Ti 45 rotor.  The supernatant was filtered through a glass filter, and then loaded 
on a Ni-NTA column pre-equilibrated with lysis buffer.  The column was washed 
with 10 column volumes of lysis buffer, followed by 10 column volumes of lysis 
buffer plus 20 mM imidazole pH=8.0. MBP-RGS2 was eluted with lysis buffer 
containing 150 mM imidazole pH 8.0, and then treated with 2% (w/w) TEV 
protease and dialyzed against lysis buffer overnight.  The dialysate was passed 
back over a Ni-NTA column equilibrated with lysis buffer to remove His-tagged 
MBP and uncut fusion protein.  RGS2 was then concentrated in a 30 kDa 
Centriprep (Millipore) and further purified using two tandem Superdex S200 
columns equilibrated with 20 mM HEPES pH 8.0, 500 mM NaCl and 5 mM DTT.  
All purification steps were performed at 4 ˚C.  The yield of pure RGS2 was 
typically ~5 mgs per liter of culture, and ΔN-RGS2 was ~3 mgs per liter.  MBP-
RGS2(1-71) is not TEV cleaved and is purified to a final yield of ~1.5 mgs per 
liter.  Due to occasional purification problems associated with RGS2 precipitation, 
we also produced RGS2 from a (His)10-RGS2 pET19B vector (ampicillin 
resistant, a gift from Scott Heximer, U. of Toronto).  Purification of (His)10-RGS2 
was as previously described (98). Rat RGS4 was purified as previously 
described, as was ΔN-RGS4(51-205), and the RGS4-N128G mutant (a gift from 
Elliot Ross, UT Southwestern)  
 
Purification of Other Proteins 
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A Gαi/q chimera, in which the amino terminal helix of Gαq is replaced with that of 
Gαi (26), a fragment of human p63RhoGEF spanning residues 149-502 
(henceforth referred to as p63RhoGEF), and GRK2 were purified as previously 
described (24, 99, 100).  Point mutants GRK2-D110A and p63RhoGEF-F471E 
were purified as described for their respective wild type proteins. 
 
Flow Cytometry Protein Interaction Assay 
 Equilibrium binding of either RGS2, RGS4, GRK2, or p63RhoGEF to Gαi/q was 
measured by a flow cytometry protein interaction assay (FCPIA).  RGS2 and 
GRK2 were fluorescently labeled with either an amine reactive probe (Alexa 
Fluor 532 carboxylic acid, succinimidyl ester) or a thiol reactive probe (Alexa 
Fluor 532 C5-maleimide).  Both probes gave similar results in binding assays.  
RGS4 and p63RhoGEF were labeled only with the thiol reactive probe, as amine 
react probes did not produce sufficient signal.  Gαi/q was biotinylated using 
biotinamidohexanoic acid N-hydroxysuccinimide ester (Sigma) initially in the form 
of a Gαi/qβγ heterotrimer, as previously described (24).  Subsequently, Gαi/q was 
biotinylated directly as a monomer because it behaved similarly and had the 
advantage of not requiring separation from Gβγ.  Biotinylated Gαi/q (b-Gαi/q, 5 nM) 
was linked to xMap LumAvidin microspheres (Luminex) and washed three times 
with 20 mM HEPES pH 8.0, 100 mM NaCl, 5 mM MgCl2, 0.1% lubrol, 2 mM DTT, 
1% BSA, 50 µM GDP plus other additions as indicated).  The indicated 
concentrations of Alexa Fluor 532 (AF)-labeled protein were then added to bead-
bound b-Gαi/q and then allowed to equilibrate for at least 30 min before being 
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processed on a Luminex 96-well plate bead analyzer.  For competition studies, 
unlabeled proteins were also added as indicated.  Longer incubation times (e.g. 
overnight) did not alter the results indicating that equilibrium was attained under 
our assay conditions.  The association of AF-labeled protein with beads is 
reported as the median fluorescence intensity (MFI) for each sample.  Each data 
point was typically measured in duplicate. 
 
Direct binding and competition data were fit by nonlinear regression either to 
one-site binding equations or to an allosteric model using GraphPad Prism (v. 
5.0a).  Allosteric modulation of AF-GRK2 binding to Gαi/q by RGS proteins was fit 
using equations 1 & 2: 
 
€ 
Y = Y0 + NS × [GRK2] +
[GRK2] × Bmax
[GRK2] + Kd ʹ′   (1) 
where Y is the total fluorescence measured, Y0 is the background fluorescence, 
NS is the linear increase in fluorescence due to non-specific binding of AF-GRK2 
to beads, and Bmax is the maximum fluorescence change due to specific binding.  
For all but one of the RGS2 dose response curves (Fig. 5B), Y0 and NS were 
directly measured and subtracted from the data to obtain specific binding.  For 
these corrected sets, Y0 and NS were fixed to be 0.  Kd´ is the apparent 
dissociation constant for AF-GRK2: 
€ 
Kd ʹ′ = Kd ×
(KA +[A])
(KA +[A] /α)    (2) 
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where Kd is the dissociation constant of AF-GRK2 in the absence of allosteric 
modulation, KA is the dissociation constant of allosteric modulator A (i.e., RGS2 
or RGS4) in the absence of AF-GRK2, and α is the cooperativity factor (101).  An 
α value greater than 1 corresponds to negative allostery.  Kd, KA and a were fit 
globally from 2-5 separate series of binding saturation curves with automatic 
outlier rejection as implemented by GraphPad Prism.  To analyze dose response 
curves using an alternative competitive model, the [A]/α term was deleted.  
Model comparisons used the F test as implemented by GraphPad Prism. 
 
Dissociation Rate of GRK2 
To determine koff for GRK2 from b-Gαi/q, 10 nM AF-GRK2 was incubated with 
bead bound b-Gαi/q for 1 or 24 hours at 4° C.  Trays were then allowed to 
equilibrate at room temperature for 30 minutes, and the dissociation of AF-GRK2 
was initiated by adding unlabeled GRK2 (final concentration 1 mM), GRK2 plus 
RGS2 (both 1 µM final), or GRK2 plus RGS4 (both 1 µM final).  The loss of 
fluorescence was measured by FCPIA at the indicated time points.  Data were fit 
to a one phase exponential decay. 
 
RESULTS 
Crystallographic Models of Gαq Effector Complexes with RGS Proteins 
Crystallographic studies demonstrated that GRK2 and p63RhoGEF both engage 
Gαq in a manner that would appear to allow the binding of the RGS domain of 
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either RGS4 (99) or RGS2 (62) to Gαq without steric overlap (Figure 6A, B).  
Models of these RGS-Gαi/q-effector complexes thus resemble the structure of the 
PDEγ-Gαi/t-RGS9 complex (Figure 6C).  The positions of the modeled RGS box 
domains in these complexes are also consistent with the predicted orientation of 
these complexes at the cell surface, in that the expected membrane binding 
elements of the RGS proteins are juxtaposed with the phospholipid bilayer.  We 
therefore initiated in vitro experiments to confirm the formation of these 
complexes and to better understand the roles of RGS proteins in modulating the 






Figure 6: Models of Gαq effector complexes with RGS proteins.  Figure by 
Dr. Aruna Shankaranarayanan.  To generate these models, the structure of Gαi/q 
in the Gαi/q-GRK2-Gβγ complex (PDB ID: 2BCJ) and Gαi/q in the 
Gαi/q-p63RhoGEF-RhoA complex (PDB ID: 2RGN) were superimposed on Gαi in 
the Gαi-RGS4 structure (PDB ID: 1AGR), which positioned RGS4 at the RGS-
binding site on the surface of Gαi/q.  There was no obvious steric overlap 
between the docked-RGS4 and either GRK2 or p63RhoGEF except for the 
protruding β6-β7 loop of the p63RhoGEF PH domain, which would come into 
contact with the α3 helix of the RGS box domain.  However, this loop can likely 
adopt many conformations.  Both the Gαq-GRK2-Gβγ and Gαq-p63RhoGEF 
peripheral membrane complexes contain markers, including the prenylation sites 
of Gγ and RhoA, that help define how the complexes could be oriented with 
respect to the cell surface.  The expected membrane surface is parallel to the top 
of each panel.  A) Model of RGS4 bound to the Gαi/q-GRK2 complex.  The PH 
domain of GRK2 was omitted for clarity.  Gα is colored cyan with orange 
β-strands, and the three switch regions (SwI, SwII and SwIII) are colored red.  
Mg2+·GDP· AlF4- in the active site of Gαi/q is shown as a sphere model.  Carbons 
are colored rose, nitrogens blue, oxygens red, Mg2+ black, Al3+ sand, and F- light 
blue.  The kinase and RGS homology domains of GRK2 are colored yellow and 
purple, respectively, and RGS4 is green.  N and C denote the observed amino 
and carboxyl termini of the proteins.  B) Model of RGS4 bound to the 
Gαi/q-p63RhoGEF complex.  The DH and PH domains of p63RhoGEF are 
colored yellow and purple, respectively.  C) Structure of the RGS9-Gαt/i1-PDEγ 
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complex (PDB ID: 1FQJ) with the Gα subunit in the same orientation as Gαi/q in 
panels A and B.  PDEγ and RGS9 are colored purple and green, respectively. 
 
Direct Binding of Fluorophore Labeled Proteins 
To observe formation of ternary RGS complexes in vitro, we chose to use a flow-
cytometry protein interaction assay (FCPIA), wherein a protein receptor is 
biotinylated and bound to streptavidin-coated beads, and the equilibrium binding 
of a fluorescently-labeled ligand is quantitatively assessed by measuring bead-
bound fluorescence in a flow cytometer (102, 103).  We first measured the direct 
association of Alexa Fluor 532 (AF)-labeled GRK2 (AF-GRK2), AF-p63RhoGEF, 
AF-RGS2 and AF-RGS4 with a biotinylated chimera of Gαq·GDP (b-Gαi/q) bound 
to the streptavidin beads and activated with AlF4- (Figure 8A).  Non-specific 
binding was determined from the increase in fluorescence using the deactivated, 
GDP-bound chimera.  We used a Gαq chimera (Gαi/q), wherein the amino 
terminal helix of Gαq is substituted with that of Gαi, because the protein can be 
expressed recombinantly at much higher yields in insect cells (26, 104).  Based 
on the available crystal structures of the Gαq-p63RhoGEF and Gαq-GRK2 
complexes (Figure 6A,B), the amino terminus of Gαq is not expected to directly 
interact with these effectors.  Furthermore, the binding of GRK2 to a different 
chimera of Gαq that included the native amino terminus of Gαq yielded similar 
dissociation constants as with Gαi/q (Figure 8).  The p63RhoGEF construct used 
in this study spans residues 149 through 502 of the full length protein and is the 
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minimal fragment required for high-affinity Gαi/q binding and activation in vitro and 
for full Gαq-mediated activation of RhoA in vivo (24).  AF-GRK2, AF-p63RhoGEF, 
AF-RGS2 and AF-RGS4 bound to Gαi/q with dissociation constants of 3, 80, 3, 
and 5 nM, respectively (Table 1, Figure 7B-D).  When comparing the binding 
curves for each of the labeled proteins, it is important to note that they are not 
expected to saturate at the same median fluorescent intensity (MFI) due to 




Figure 7: Direct binding of fluor-labeled proteins to Gα i/q.  A) Scheme 
depicting measurement of equilibrium binding by FCPIA.  Total binding was 
measured on a Luminex flow cytometer as the median fluorescence intensity 
(MFI) of AF-labeled proteins associated with AlF4--activated Gαi/q (+AMF) that 
was biotinylated and bound to streptavidin coated beads.  Non-specific binding 
was measured using bead-bound deactivated Gαi/q·GDP (-AMF).  Total and non-
specific binding curves for B) RGS2 and ΔN-RGS2, C) RGS4 and ΔN-RGS4, D) 
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GRK2, and E) p63RhoGEF.  The data shown are mean ± SEM values 
representative of three or more experiments, each run in duplicate. 
 
Table 1: Affinity of effectors and RGS proteins for biotin-Gα i/q. Ki values 
were determined with the Cheng-Prusoff equation using the corresponding Kd 







RGS2 2.5 ± 1.3 nM 6.4 ± 5.9 nM 
ΔN-RGS2 37 ± 12 nM -- 
RGS4 5.3 ± 3.0 nM 8.6 ± 4.7 nM 
ΔN-RGS4 51 ± 8.3 nM -- 
GRK2 3.2 ± 1.7 nM 3.3 ± 1.6 nM 








Figure 8:  RGS2 and GRK2 binding to a Gαq variant with a native N-
terminus.  The Gαi/q chimera was used in our binding studies due to the much 
higher yields of protein from purification.  A) RGS2, B) ΔN-RGS2, and C) GRK2 
bind to a variant of Gαq that has a native amino terminus.  The binding affinities 
are to that of Gαi/q with Kd’s of approximately 3.0 nM, 30.0 nM, and 1.0 nM, 
respectively.  The curves have been background subtracted.  The data shown is 
mean ± SEM of duplicate samples from a representative experiment of n≥3 
performed.   
 
Competition Assays  
Because an AF-labeled protein may not bind with the same affinity as the 
unmodified protein, we used homologous competition experiments (Figure 9A) to 
determine the equilibrium dissociation constants for GRK2, p63RhoGEF, RGS2, 
and RGS4.  In these experiments, increasing amounts of unlabeled protein is 
used to compete against the AF-labeled protein, whose concentration is held at 
near its measured dissociation constant (Table 1, Figure 8).  The resulting IC50 
values are then converted to Ki values using the Cheng-Prusof equation.  Ki 
values of 3, 50, 6 and 9 nM were measured for GRK2, p63RhoGEF, RGS2 and 




Figure 9: Competition of GRK2 or p63RhoGEF with RGS proteins for b-
Gα i/q.  A) Scheme depicting FCPIA competition experiments. Increasing 
amounts of unlabeled protein were mixed with an AF-labeled protein fixed at a 
concentration near its measured Kd for Gαi/q.  Subsequently, bead-bound b-
Gαi/q·AlF4- was added and allowed to equilibrate for at least 30 minutes before 
measurement.  The data was normalized to the uninhibited maximum MFI value 
for each curve.  The data, representative of three or more experiments run in 
duplicate with mean ± SEM shown, were fit to sigmoidal dose-response curves.  
B) Competition of unlabeled GRK2, RGS2, RGS2-N149D, RGS4, and RGS4-
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N128G with 5 nM AF-532 GRK2 for binding to b-Gαi/q·AlF4-.  C-E) Competition of 
(C) 50 nM AF-p63RhoGEF, D) 10 nM AF-RGS2, and E) 10 nM AF-RSG4 with 
unlabeled p63RhoGEF, GRK2, RGS2, or RGS4 for binding to b-Gαi/q·AlF4-. 
 
We next used FCPIA to examine whether RGS proteins could modulate 
formation of the Gαi/q-GRK2 complex.  Both RGS2 and RGS4, but not inactive 
point mutants of RGS2 and RGS4 (N149D (61) and N128G (105), respectively), 
could compete with AF-GRK2 binding in the FCPIA assay (Figure 9B).  RGS4 
could only inhibit AF-GRK2 binding to about 50%, while RGS2 inhibited nearly to 
completion.  Conversely, GRK2 was not an efficacious inhibitor of the binding of 
either AF-RGS2 (Figure 9D) or AF-RGS4 (Figure 9E) to Gαi/q at the 
concentrations tested.  Taken together, these data are most consistent with 
RGS2 and RGS4 acting as negative allosteric modulators of AF-GRK2 binding to 
Gαi/q. 
 
Next, we tested if RGS proteins could modulate formation of the Gαi/q-
p63RhoGEF complex.  As a control, we tested if GRK2 acted as an orthosteric 
inhibitor of AF-p63RhoGEF binding, as would be expected for two proteins that 
bind at the same site (Figure 6).  Indeed, both GRK2 and unlabeled p63RhoGEF 
fully inhibited binding of AF-p63RhoGEF (Figure 9C).  Higher concentrations of 
p63RhoGEF were required for full competition, consistent with its ~10-fold higher 
Kd (Table 1).  Both RGS2 and RGS4 could compete with AF-p63RhoGEF binding 
to Gαi/q (Figure 9C), but neither could fully inhibit binding.  Similar to GRK2, 
 
 38 
p63RhoGEF could not efficiently compete against AF-RGS2 and AF-RGS4 
binding at the concentrations tested (Figure 9D,E, respectively).  The data is thus 
consistent with RGS2 and RGS4 acting as negative allosteric modulators of 
p63RhoGEF-Gai/q complex formation.  
 
Formation of Ternary Complexes by FCPIA 
The allosteric behavior observed in the competition experiments represents only 
indirect proof of the formation of a ternary RGS-Gαi/q-GRK2/p63RhoGEF 
complex.  To use FCPIA to directly test for the formation of an RGS2/4-Gαi/q-
GRK2 complex, biotinylated RGS proteins (b-RGS2 or b-RGS4) were bound to 
streptavidin-coated beads, and then incubated in the presence of a fixed 
concentration of unlabeled Gαi/q and increasing amounts of AF-GRK2 or AF-
p63RhoGEF (Figure 10A).  In this experiment, fluorescence should only be 
observed when a ternary complex is formed, with Gαi/q bridging the bead-bound 
and AF-labeled proteins.  As a control, we first showed that GRK2 has no 
measurable affinity for RGS proteins, because in the absence of Gαi/q the 
fluorescence signal was similar to that of beads alone (data for RGS4 is shown in 
Figure 10B).  In the presence of Gαi/q·AlF4-, b-RGS4 exhibited saturable binding 
to AF-GRK2 (Figure 10B,C).  The measured Kd for AF-GRK2 binding to RGS4-
Gαi/q under these conditions was ~4-fold (n=4) higher than its intrinsic 
dissociation constant for Gαi/q.  This could be a direct result of allosteric 
modulation of the GRK2-binding site on Gαi/q by RGS4.  Conversely, RGS2 
exhibited no or little ability to form an analogous ternary complex under the 
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conditions tested (Figure 10C), perhaps consistent with the fact that it exhibits 
stronger negative allosteric effects than RGS4 (Figure 9C). 
 
Analogous experiments with p63RhoGEF gave similar but less reproducible 
results, most likely due to the lower maximal signal to noise we routinely observe 
using AF-p63RhoGEF (cf. Figure 7D & E) and the lower affinity of p63RhoGEF 
for Gαi/q relative to GRK2 (Table 1).  However, we could directly confirm the 
formation of an RGS4-Gai/q-p63RhoGEF complex by size exclusion 
chromatography (Figure 10D,E).  In the experiment shown, a complex of AlF4--
activated Gαi/q with p63RhoGEF was formed, and then excess GDP and Mg2+ 
was removed before addition of apo-RhoA (the presence of GDP and Mg2+ 
inhibits RhoA binding to p63RhoGEF).  All four proteins eluted as a single peak 
from two tandem S200 gel filtration columns (Figure 10D,E).  Because Gαi/q was 
limiting, peaks corresponding to free p63RhoGEF, RGS4 and RhoA were 
observed at lower molecular weights (Figure 10E).  Thus, we have both direct 
(Figure 10) and indirect evidence (Figure 9) that RGS4 has the ability to form 




Figure 10: Formation of ternary and higher order RGS complexes with 
Gα i/q.  A) Scheme depicting the direct measurement of ternary complex 
formation using FCPIA.  B) AF-GRK2 does not bind to RGS4 in the absence of 
Gαi/q·AlF4-.  Shown is the total binding of AF-GRK2 to LumAvidin beads ± b-
RGS4 in the presence or absence of activated Gαi/q.  The measured 
fluorescence of AF-GRK2 binding to beads plus b-RGS4 was similar to that of 
binding to beads alone.  C) Specific binding of AF-GRK2 to RGS4-Gαi/q·AlF4-.  In 
this experiment, 5 nM b-RGS2 or b-RGS4 was coupled to beads, and then added 
to AF-GRK2 ± 100 nM Gαi/q·AlF4-.  RGS2 exhibited little or no affinity under these 
conditions.  Nonspecific binding was measured as the binding of AF-GRK2 to b-
RGS2/4 in the absence of Gαi/q.  Data shown is mean ± SEM typical of 4 
experiments, each run in duplicate.  D) Isolation of an RGS4-Gαi/q–p63RhoGEF-
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RhoA quaternary complex by size exclusion chromatography.  Ternary 
complexes of RGS4-Gαi/q–p63RhoGEF can also be purified (data not shown).  
(E) Peak fractions of the size exclusion run analyzed by SDS-PAGE.  Proteins 
were visualized by Coomassie blue stain.  'M' denotes the protein standard 
marker lane and 'L' the reaction mix load.  (Experiments in panels D and E were 
performed by Dr. Aruna Shankaranarayanan) 
 
Role of the N-terminus of RGS2 and RGS4 
We had thus far only observed direct ternary complexes with RGS4 in our FCPIA 
pull-down assay and size exclusion experiments (Figure 10).  Although one might 
expect RGS2 and RGS4 to function similarly, in the absence of any RGS2-Gα 
crystal structures, it remained possible that RGS2 interacts with Gαi/q in a way 
that overlaps with the effector binding site.  The N149D mutant of RGS2, 
equivalent to N131D point mutant in RGS16 (61) and analogous to the N128G 
mutant of RGS4 (105), alters a key residue that packs in the interface between 
RGS proteins and Gα subunits (99).  As described earlier, neither RGS2-N149D 
nor RGS4-N128G could compete against AF-GRK2 for binding Gαi/q (Figure 9B).  
Thus, the RGS box domains of RGS2 and RGS4 likely interact in the same way 
with the switch regions of the Gα subunit (Figure 6).  However, the amino 
terminal regions of these RGS proteins, which are not typically ordered in crystal 
structures, also have the potential to influence their behavior.  In the R4 family of 
RGS proteins, an amphipathic helix in the amino terminus is postulated to direct 
targeting of the RGS protein to membranes (103, 106-108) or to the intracellular 
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loops of GPCRs (109), or to inhibit adenylyl cyclase (110) and the Ca2+ channel 
TRPV6 (111).  In our direct binding experiments, deletion of the amino termini of 
RGS2 (ΔN-RGS2) and RGS4 (ΔN-RGS4) decreased affinity for Gαi/q 15- and 10-
fold, respectively, compared to the full-length proteins (Figure 7B-C, Table 1). 
Thus, the amino termini of RGS2 and RGS4 either directly or indirectly contribute 
to binding affinity for Gαi/q.  To test the possibility that the amino terminus of 
RGS2, but not RGS4, docks with the effector-binding site of Gαq and thereby 
inhibits effector binding, we examined the binding of RGS2 and RGS4 to a panel 
of Gαq mutants known to be defective in effector binding (A253K, T257E, Y261N, 
and W263D) (112) and (A. Shankaranarayanan, unpublished data).  In a bead 
pull-down assay, all of these mutants appeared to bind RGS2 and RGS4 equally 
well (data not shown).  Thus, we have no evidence that RGS2 and RGS4 bind in 
a fundamentally different way to Gαq.  It is possible that the amino termini of 
RGS2 and RGS4 contribute to binding in conjunction with the RGS box through 
non-specific interactions (note higher non-specific binding for full length RGS2 
and RGS4 in Figure 7B-C). 
 
Allosteric Modulation between the RGS and Effector Binding-Sites 
To more rigorously examine the allostery mediated by RGS2 and RGS4 on Gαi/q 
complex formation, we used FCPIA to measure the binding of AF-GRK2 to b-
Gαi/q·AlF4- in the presence of increasing concentrations of either RGS2 or RGS4 
(Figure 11A,B).  As expected for negative allosteric modulators (101), increasing 
amounts of RGS2 and RGS4 induced increases in the apparent Kd of AF-GRK2 
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that saturated at high concentrations of RGS protein.  RGS2 (Figure 11A) was 
more potent than RGS4 (Figure 11B).  The data were globally fit to either a 
simple allosteric ternary complex model (Figure 11,B) or a direct competition 
model (Figure 12).  The curves were best fit by the allosteric model (101) with F 
statistics of 61 and 43 for RGS2 and RGS4, respectively, both with p values < 
0.0001.  The cooperativity factor (α) for RGS2 was estimated to be 22 ± 2.3 (5 
separate series of curves) and that of RGS4 to be 5 ± 0.5 (2 separate series of 
curves).  Thus, RGS2 and RGS4 appear to lower the apparent affinity of GRK2 
for Gαi/q by up to ~22- and 5-fold, respectively.  These allosteric constants were 
also consistent with the relative extents by which RGS2 and RGS4 inhibited 
binding of AF-GRK2 in competition curves (Figure 9B).  The extracted 
dissociation constants of GRK2 from the global fits were 3 ± 0.2 and 5 ± 0.5 nM 
for the RGS2 and RGS4 curves, respectively.  The estimated dissociation 
constants for RGS2 and RGS4 were 10 ± 1 and 80 ± 20 nM, respectively.  The 
GRK2 and RGS2 Kd values are similar to the dissociation constants measured by 
competition (Table 1) and confirm the validity of the fit to the RGS2 dose 
response curves.  The 10-fold higher Kd calculated for RGS4 is likely a 
consequence of the smaller allosteric effect of RGS4 and hence greater 
inaccuracy in the global fit.  Analogous experiments for AF-p63RhoGEF binding 
were not attempted because of its intrinsically lower signal-to-noise ratio in 




Another definitive characteristic of an allosteric modulator is to change the rate of 
dissociation of an orthosteric ligand (113).  We therefore used FCPIA to measure 
the dissociation rate of AF-GRK2 from Gαi/q in the presence of saturating 
amounts of unlabeled GRK2, GRK2+RGS2 or GRK2+RGS4  (Figure 11C).  
RGS2 enhanced the dissociation rate of GRK2 from 0.05 to 0.17 min-1, or 3.3 
fold, ANOVA p<0.0001.  The slight increase in the dissociation rate of GRK2 in 
the presence of RGS4 (0.065 min-1) was not statistically significant.  A 3.3-fold 
increase in the rate of dissociation is not enough to account for the 22-fold 
decrease in affinity of GRK2 for Gαi/q mediated by RGS2 (Figure 11A).  Thus, 
RGS2 must also decrease the rate of association of GRK2 with Gαi/q by ~6 fold.  
The significant increase in koff mediated by RGS2 (Figure 11C), the superior fits 
of our data to an allosteric model (Figure 11A,B, Figure 12), and the allosteric 
behavior exhibited by our competition experiments (Figure 8) all strongly suggest 
that RGS2 and RGS4 are strong and weak allosteric modulators, respectively, of 
the effector-binding site of Gαq.  The fact that RGS2 ternary complexes have 
thus far proved more difficult to demonstrate directly may simply reflect this 
stronger allosteric modulation and the correspondingly greater rates that proteins 




Figure 11: Negative allosteric modulation between RGS proteins and GRK2 
for Gα i/q binding.  A-B) Dose-response curves of AF-GRK2 binding to b-Gαi/q in 
the presence of increasing concentrations of either A) RGS4 or B) RGS2.  A 
model of negative allosteric modulation best fit the data, in part because 
 
 46 
increasing concentrations of RGS protein eventually saturate in their ability to 
increase the apparent Kd of AF-GRK2.  The data shown is typical of 2 (RGS4) or 
5 (RGS2) sets of experiments, wherein each individual curve was measured in 
duplicate.  C) RGS2 modulates the intrinsic rate of GRK2 dissociation from Gαi/q.  
The dissociation rate of AF-GRK2 (10 nM) from bead-bound b-Gαi/q·AlF4- was 
measured in the presence of either 1 µM GRK2, 1 µM GRK2 plus 1 µM RGS2, or 
1 µM GRK2 plus 1 µM RGS4 using FCPIA.  The data shown is mean ± SEM 
representative of one of three experiments, each run with duplicate samples.  
RGS2 increased koff of GRK2 from 0.054 ± 0.003 min-1 to 0.16 ± 0.039 min-1 




Figure 12: Dose-response curves of AF-GRK2 binding to b-Gα i/q are fit 
poorly by a competitive model.  The data in these panels are the same as 
shown in Figure 11A and Figure 11B, but Eq. 2 was modified such that [A]/α=0. 
 
Modulation of GAP Activity by GRK2 and p63RhoGEF 
The allostery between the RGS and effector binding sites of Gαi/q could also 
manifest itself in the activity of the respective proteins.  We therefore tested 
whether GRK2 and p63RhoGEF could modulate the GAP activity of RGS-Gαq 
complexes.  GAP assays were performed using the GTPase-deficient 
Gαi/qR183C mutant (114).  Arg183 resides at the beginning of switch I in Gαq and 
stabilizes the negative charge on the γ-phosphate of GTP during the transition 
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state of GTP hydrolysis.  Arg183 does not interact with effectors or with RGS 
proteins in crystal structures, and  the Gαq R183C mutant hydrolyses GTP 
slowly, facilitating measurement of GAP activity, but still activates its effectors 
PLCβ and p63RhoGEF, binds GRK2, and responds to the GAP activity of RGS 
proteins (24, 29, 115).  We first compared the GAP activity of 200 nM RGS2, 
RGS4 and ΔN-RGS2 (Figure 13A).  Under our experimental conditions, 
Gαi/qR183C hydrolyzed GTP at a basal rate of 0.004 ± 0.001 min-1.  Addition of 
200 nM RGS2 stimulated this rate 30-fold, while 200 nM RGS4 produced an 11-
fold increase.  Despite the lower apparent affinity of ΔN-RGS2 protein for b-
Gαi/q·AlF4- (Table 1), this protein had higher GAP activity than wild-type RGS2 




Figure 13: Modulation of GAP activity by GRK2 and p63RhoGEF.  Data by 
Dr. Aruna Shankaranarayanan.  A) Comparison of the GAP activity of 200 nM of 
each RGS protein on Gαi/qR183C.  In this experiment, data were fit to a one 
phase exponential to give rate constants of 0.005 (basal), 0.12 (RGS2), 0.044 
(RGS4), and 0.31 (ΔN-RGS2) min-1.  B) The effect of GRK2 on the GTPase 
activity of Gαi/qR183C·GTP in the presence and absence of 100 nM RGS protein.  
The amount of 32P released at 2, 5, 10, and 15 minutes were quantified and fit to 
lines.  The slopes were then normalized either with respect to basal activity 
(GRK2 alone curves) or with respect to the 100 nM RGS slope (GRK2 + RGS 
protein curves).  The 20 nM GRK2 time point in the RGS4 curve and the 20 and 
200 nM time points in the RGS2 curve are from a single experiment.  The 
remaining time points represent the means ± SD of 2-7 experiments.  C) The 
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effect of p63RhoGEF on the GTPase activity of Gαi/qR183C·GTP in the presence 
or absence of RGS proteins.  The 200 nM time point in the RGS4 curve and the 
50 and 200 nM time points in the RGS2 curve are from a single experiment.  The 
remaining time points represent the means ± SD of 3-6 experiments.  D) The 
enhancement of RGS4-stimulated GTP hydrolysis by GRK2 and p63RhoGEF is 
specific. The GRK2-D110A and p63RhoGEF-F471E Gαq-binding deficient 
mutants, used at the same concentrations as their wild-type equivalents, were 
deficient in stimulating GTP hydrolysis.  Data points represent the mean fold over 
RGS ± SD (n=3).  Data were analyzed with a Tukey’s post-test.  Three asterisks 
indicates a significant difference between the indicated columns at the p<0.001 
level. 
 
To avoid saturating the GAP activity, we measured GTP hydrolysis on 
Gαi/qR183C using RGS proteins at half the prior concentration (100 nM), at which 
the apparent rate constants were 0.06 ± 0.02, 0.012 ± 0.001 and 0.16 ± 0.02 min-
1 for RGS2, RGS4, and ΔN-RGS2, respectively.  This also enabled us to 
measure the RGS-stimulated release of 32P over a 15 min time course with 
approximately linear kinetics.  In the absence of RGS proteins, neither GRK2 nor 
p63RhoGEF significantly stimulated GTP hydrolysis on Gαi/qR183C (Figure 13B 
and C).  However, at concentrations up to 50 nM, GRK2 acted synergistically 
with RGS4 and stimulated the rate of GTP hydrolysis up to a maximum of ~4-fold 
over RGS4 alone.  Smaller magnitude effects were observed with p63RhoGEF in 
place of GRK2, with the maximal extent of activation being 1.4 fold at 100 nM 
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p63RhoGEF (Figure 13C).  Point mutants of GRK2 and p63RhoGEF that are 
deficient in binding Gαq (D110A and F471E, respectively) did not similarly 
enhance the rate of GTP hydrolysis by RGS4 (Figure 13D), indicating that the 
synergistic effects of 50 nM GRK2 and p63RhoGEF are specific.  The 4-fold rate 
enhancement we measured for RGS4 and GRK2 is similar to that observed for 
the cooperative interaction of RGS9 and PDEγ with Gαt (84, 85). Interestingly, 
whereas GRK2 and p63RhoGEF appeared to have only small effects on the 
affinity of RGS4 for Gαq (Figure 9E), PDEγ enhanced the affinity of RGS9 for Gαt 
(86).  Obviously, affinity for the Gαi/q·AlF4- state is not completely correlated with 
GAP activity.  In contrast to RGS4, RGS2-mediated stimulation of GTP 
hydrolysis was not significantly affected at concentrations of either GRK2 or 
p63RhoGEF up to 100 nM (Figure 13B,C). 
 
At the higher concentrations of GRK2 or p63RhoGEF, the GTP hydrolysis rates 
mediated by RGS2 and RGS4 gradually decrease.  Because 400 nM GRK2-
D110A and p63RhoGEF-F471E did not have this effect, (Figure 14), the slow 
decrease in the rate of GTP hydrolysis appears to require formation of a Gαq-
GRK2 or Gαq-p63RhoGEF complex.  Biphasic curves such as that exhibited by 
GRK2 and RGS4 (Figure 13B) could imply multiple binding sites for GRK2 and 
p63RhoGEF on Gαi/q, but this does not seem structurally reasonable.  The 
decrease in GTP hydrolysis was also not dependent on the amino terminus of 
the RGS protein, as both ΔN-RGS2 and full length RGS2 were inhibited at high 
GRK2 concentrations (Figure 13B, Figure 14).  Because the GAP assay is not 
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performed at equilibrium, it is possible that the slow decrease in the rate of GTP 
hydrolysis is due to a decrease in the rate of association of RGS protein at high 
concentrations of GRK2 or p63RhoGEF (113). 
 
Figure 14: Decrease in RGS2-mediated GTP hydrolysis at higher 
concentrations of GRK2 and p63RhoGEF is specific.  Data by Dr. Aruna 
Shankaranarayanan.  The GRK2-D110A and p63RhoGEF-F471E Gαq-binding 
deficient mutants could not inhibit ΔN-RGS2-mediated GTP hydrolysis to the 
same extent as their wild-type equivalents.  Data points represent the mean fold 
over RGS ± S.D (n=3).  Three asterisks indicates a significant difference between 




Inhibition of Gαq-mediated p63RhoGEF Activity by RGS2 and RGS4 
We also tested whether RGS proteins could modulate effector activity in a GAP-
independent manner.  Although there is no observable increase in GRK2 activity 
as a function of Gαq that can be readily measured in vitro (29), we could examine 
the effect of RGS2 and RGS4 on the Gαi/q·AlF4--stimulated nucleotide exchange 
activity of p63RhoGEF.  In this assay, nucleotide exchange onto RhoA was 
measured by an increase in fluorescence polarization of a fluorescently labeled 
GTPγS nucleotide as it binds RhoA.  Both RGS4 and RGS2 can dramatically 
reduce the activity of Gαi/q-p63RhoGEF (Figure 15).  The inhibition was specific, 
because 2 µM RGS2-N149D and 2 µM RGS4-N128G had no affect on the rate of 
Gαi/q-stimulated GEF activity on RhoA.  Experiments in which the addition of 
RGS protein was delayed by one or two hours did not generate differences in 
inhibition (data not shown), suggesting that the observed loss of exchange 
activity is not a kinetic artifact due to changes in association or dissociation 
kinetics.  Thus, it appears that RGS proteins are indeed able to modulate the 
activity of p63RhoGEF through both an allosteric and a GAP mechanism.  These 
data are consistent with reports of RGS2 and RGS4 serving as effector 
antagonists of PLCβ (64, 95, 96).  However, because PLCβ possesses its own 
intrinsic GAP domain (114), it is not yet clear whether the antagonism exhibited 




Figure 15: Inhibition of Gα i/q-stimulated p63RhoGEF activity by RGS2 and 
RGS4.  Data by Dr. Aruna Shankaranarayanan.  Nucleotide exchange on RhoA 
was monitored by the increase in fluorescence millipolarization (mP) of BODIPY 
FL GTPγS upon binding RhoA.  The resulting data were fit as one phase 
exponentials and are expressed here as the average fold over basal exchange ± 
SD from three independent experiments, each measured in triplicate.  Two 
asterisks indicate an ANOVA p<0.01 and three asterisks an ANOVA p<0.001 




Allosteric Behavior of Ternary Complexes 
Positive allosteric behavior was previously observed in the ternary complex 
formed by Gαt, PDEγ and RGS9.  Negative allostery was exhibited between 
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PDEγ and other RGS proteins tested, including RGS4 and RGS16 (85, 87).  Our 
data indicates that Gαq also can form ternary complexes with RGS proteins and 
proteins that bind at its effector-binding site.  In these complexes, both RGS2 and 
RGS4 negatively modulate the binding of GRK2 to Gαi/q (Figure 11).  
Competition experiments indicated that RGS2 and RGS4 also negatively 
modulate the binding of p63RhoGEF (Figure 9).  The allostery of these ternary 
complexes also had striking effects on the activity of the RGS and effector 
proteins.  RGS4 GAP activity on Gαq was potentiated by GRK2 and p63RhoGEF, 
while that of RGS2 was unaffected or slightly decreased (Figure 11B,C).  The 
Gαq-stimulated activity of p63RhoGEF was specifically inhibited by both RGS2 
and RGS4 (Figure 13).  Because Gαt is a representative member of the Gαi 
family, and Gαq of the Gαq/11 family, allosteric interplay between the RGS- and 
effector-binding sites appears possible for all Gα subunits that bind RGS 
proteins.  The most likely conduit for such allosteric communication is the amino 
terminus of the helix at the beginning of switch II.  This region is conformationally 
responsive to the nucleotide-bound state of Gα and is bracketed by interactions 
with both RGS protein and effector in the RGS9-Gαt-PDEγ complex (Figure 5 
and Figure 6).  This part of switch II also contributes a critical glutamine residue 
to the hydrolytic site of Gα (16).  Thus, subtle changes in the conformation of this 
region could have profound effects on the affinity of effectors and GAPs and on 




Despite the great structural diversity exhibited by the protein domains that 
interact with the effector-binding sites of Gαq and Gαi/t (Figure 6), the ability to 
form ternary complexes between effectors, Gα subunits and RGS proteins 
appears remarkably well conserved.  What physiological roles might these 
ternary complexes serve?  Segregation of the effector and RGS binding sites on 
the Gα subunit enables RGS proteins to modulate signal transduction of effector-
bound Gα subunits.  This may enable faster rates of signal termination because 
RGS proteins would not have to compete for the same site as effectors.  The 
enhancement of the GAP activity of RGS9 on Gαt mediated by PDEγ is required 
for physiological rates of signal termination in rod cells.  Because of this 
requirement, the synergy between PDEγ and RGS9 has been proposed to be a 
mechanism that helps to ensure that phototransduction occurs through PDE 
before GAP activity is brought to bear, preventing a potential short-circuit (87, 
116).  Thus, Gαt, PDEγ and RGS9 collaborate to achieve both efficient signal 
tranduction (no short circuit) and high time resolution (rapid GTP hydrolysis on 
Gαt) (117).  Gαq is the Gα subunit responsible for invertebrate phototransduction 
and, from an evolutionary perspective, may have similar requirements for 
efficient effector coupling and rapid signal termination. Invertebrate 
phototransduction is mediated by a phospholipase C enzyme which, like 
vertebrate PLCβs, has its own intrinsic GAP domain (118).  Indeed, vertebrate 
PLCβ1 can stimulate GTP hydrolysis on Gαq by three orders of magnitude (119) 
to rates similar to the rate of signal termination in invertebrate vision (120).  The 
presence of both a GAP and effector in the same molecule ensures both signal 
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transduction and high time resolution.  However, like PDEγ, GRK2 and 
p63RhoGEF have little or no GAP activity for Gαq in the absence of RGS 
proteins.  When challenged by RGS4, which can accelerate GTP hydrolysis on 
Gαq at even higher rates than PLCβ1 (119), a mechanism to avoid a short circuit 
of the signals passed by p63RhoGEF and, perhaps, GRK2 may become 
necessary.  The synergistic GAP activity exhibited by RGS4 and 
GRK2/p63RhoGEF could therefore be a mechanism to keep the rates of Gαq 
GTP hydrolysis lower unless an effector is already engaged with Gαq.  The fact 
that RGS proteins can in addition allosterically affect p63RhoGEF activity (Figure 
14) is also evidence that RGS proteins can serve a role in tuning, rather than 
simply squelching, Gq signal transduction.  In fact, if Gαq is indeed rapidly cycled 
by GPCRs (16, 93), then tuning the amplitude of the signal may be the ultimate 
manifestation of RGS activity on Gαq. 
 
Differential Allostery Exhibited by RGS2 and RGS4 
RGS2 exhibits GAP activity that is not positively cooperative with effector-binding 
(Figure 13) and has a much stronger negative allosteric effect than RGS4 on the 
affinity of proteins that bind at the effector-site of Gαq (Figure 9, Figure 11).  
Clearly, two different RGS proteins, even members of the same RGS subfamily, 
can have strikingly different allosteric effects.  The ability to form distinct 
complexes between Gαq, effectors and RGS proteins with different allosteric 
properties may ultimately allow for a greater ability to tune the strength and 
duration of signal transduction to meet the specific requirements of a particular 
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cell-type or physiological setting.  For example, RGS2 may be upregulated by 
cells in situations when a short-circuit of Gαq signaling would be beneficial. 
 
The Role of GRK2 as a Bona Fide Gαq Effector. 
GRK2 and p63RhoGEF are similar not only in the manner in which they bind Gαq 
(Figure 6) but also in the way their binding is allosterically regulated by RGS 
proteins.  Our data therefore supports the idea that GRK2 is a bona fide effector 
target of Gαq whose activity can potentially be modulated by the action of RGS 
proteins in vivo.  Because Gαq as of yet has no obvious effect on the catalytic 
activity of GRK2 in vitro (29), the role of Gαq in regulating GRK2 signaling might 
simply be translocation of the soluble enzyme to cell membrane where its targets 
are found.  Although recruitment of the RGS homology domain of GRK2 to the 
membrane by activated Gαq has been observed in cells (27, 121), membrane 
translocation of GRK2 has historically been attributed to Gβγ subunits (122, 123).  
Under conditions near physiological ionic strength, GRK2 binds to Gαi/q·AlF4- with 
>10-fold higher affinity than to Gβγ subunits in detergent micelles (V. Tesmer, 
unpublished data).  Gαq might therefore be the principal route by which GRK2 is 
recruited to membranes when Gq-coupled receptors are activated, especially if 
Gβγ were involved in interactions with other peripheral membrane proteins (e.g. 
PLCβ).  However, even if Gβγ were solely responsible for membrane 
translocation of GRK2, RGS-Gαq complexes could still modulate GRK2 activity 
by controlling how long Gβγ interacts with GRK2.  RGS-accelerated GTP 
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hydrolysis, allosterically tuned by GRK2, would more rapidly return Gαq to its 
deactivated GDP-bound state, which would then sequester Gβγ from GRK2.  
 
The best-established “downstream” target of GRK2 is of course an activated 
GPCR.  Phosphorylation of these GPCRs recruits arrestin, uncouples G proteins 
from the receptor, targets the receptor for clathrin-mediated endocytosis, and 
activates arrestin-mediated pathways.  The idea that RGS proteins might 
regulate this activity is an intriguing one, and suggests that conditions that lead to 
upregulation of RGS proteins might also lead to a loss of GRK2 and GRK3-
mediated phosphorylation of at least Gαq-coupled GPCRs.  We speculate that 
this might offer a protective effect against relatively transient changes in cellular 
environment where a given cell might want to suppress signaling by Gαq yet 
preserve receptor number and function at the membrane. 
 
Summary 
In summary, our data support the idea that RGS proteins are the third component 
of a ternary complex formed by Gαi and Gαq subunits during active signal 
transduction.  Because GPCRs are also reported to interact with RGS proteins, 
an activated receptor may be a fourth obligate member of this complex.  Not only 
has nature mandated that effectors and RGS proteins co-exist in complexes with 
Gαq, but also it appears that Gαq subunits have evolved to adopt a specific 
orientation at the membrane while engaging effectors (Figure 6).  This orientation 
may be conserved for the purpose of promoting productive interaction with 
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membrane- or receptor-associated RGS proteins, and may also provide the 
underlying molecular basis for the rapid nucleotide cycling of Gα subunits that 




Our current findings show that ternary complexes can be formed between Gαq, 
RGS2/4, and GRK2/p63RhoGEF in a way that is similar to that of RGS9-Gαt-
PDEγ.  Intriguingly, our data corroborate the hypotheses that both RGS2 is 
selective for Gαq versus RGS4 and that GRK2 is a bona fide effector of Gαq.  It is 
well known the RGS2 and RGS4 differ in potency as inhibitors of Gαq versus Gαi 
signaling (62, 63).  However, it is not clear mechanistically how the selectivity is 
achieved.  One model suggests that selectivity could be achieved by differences 
in conformation of the switch I region in Gαq vs Gαi.  Another model suggests 
that sequence differences in residues of RGS2 and RGS4 that are implicated in 
binding an invariant threonine residue in the Gα subunits are responsible for the 
selectivity.  Indeed, mutations of two of these residues (RGS2-C106S and RGS2-
N184D) have been shown to increase the binding affinity of RGS2 for Gαi1 (62).  
Additionally, RGS2-Glu191 has been implicated in selectivity through possible 
interactions with the α-helical domain on the Gα subunit (63).  It would be 
interesting to test these mutations to see if the greater negative allostery of 
RGS2 could be lessened to that of RGS4.  Figure 16 shows the residues in 
RGS2 and RGS4 that have been implicated in Gαq selectivity (colored purple), 
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additionally, residues that are in close proximity to effector binding (colored red) 
could also play a role in the observed allostery due to steric hindrance towards 
effector binding.  
 
The simultaneous association of Gαq and Gβγ with GRK2 is a feature that is 
shared with other classic effectors such as adenylyl cyclase and PLCβ.  To date 
no signaling pathway has been attributed to Gαq mediated activation of GRK2, 
although, GRK2 has been shown to phosphorylate IRS-1 (90), ezrin (92), p38 
MAP kinase (91) in response to activation of Gq-coupled receptors.  Indeed, the 
role of the Gαq-GRK2 activation may simply be regulating the phosphorylation of 
GPCRs by helping to recruit GRK2 to the membrane.  Another possible future 
direction would therefore be to determine if RGS interactions with Gαq are 
capable of regulating phosphorylation of GPCRs by GRK2 providing a novel 
alternative pathway for differential handling of feedback inhibition and longer term 
regulation.   
 
Figure 16: Sequence alignment of RGS2 and RGS4.  Sequence alignment of 
human RGS2 and rat RGS4 was performed using Clustalw 
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(www.ebi.ac.uk/clustalw).  The secondary structure α-helices are shown as blue 
cylinders labeled as α1-α9 for the traditional helices based on the RGS4 
structure and αA for the amphipathic helix in the N-terminal region of RGS2.  
Residues colored in purple have been shown in the literature to be important in 
the selectivity of RGS2 versus RGS4 for the binding of Gαq (62, 63).  Residues 
colored in red are located in the α5-α6 loop and come into the closest contact 
with the effector binding site (based on GRK2/p63RhoGEF). 
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Chapter 3  
Screening for Small Molecule Inhibitors 
of the Gαq-GRK2 Protein-Protein Interaction 
 
BACKGROUND AND PROJECT GOALS 
Physiological Roles of Gαq and GRK2 
The heterotrimeric G protein Gq (Gαqβγ) is a key regulator of cardiovascular 
development and function.  Signaling through Gq-coupled receptors is 
responsible for regulating a diverse range of responses in the cardiovasculature 
including platelet activation (20), heart development, and cardiac hypertrophy 
(124-128).  The classic downstream effector of the Gαq subunit is phospholipase 
Cβ (PLCβ).  Activation of PLCβ leads to the hydrolysis of membrane bound 
phosphotidylinositol-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 1, 
4, 5-triphosphate (IP3), which leads to activation of the protein kinase C pathway 
(Figure 17).  It is now known that Gαq also interacts with other effector enzymes 
including a family of RhoA mediated nucleotide exchange factors.  This includes 
p63RhoGEF (112, 129), which uses its catalytic Dbl homology domain (DH) to 
catalyze the nucleotide exchange of RhoA, consequently causing cytoskeleton 





Figure 17: Signal transduction through Gq-coupled receptors.  After 
activation of a Gq-coupled receptor, Gαq·GTP dissociates from Gβγ and the two 
proteins can engage downstream effector targets.  All three effectors have 
distinct downstream targets and sometimes two different Gαq effectors are 
required for a proper physiological response.  Despite this, both GRK2 and 
p63RhoGEF have been shown to compete with PLCβ for Gαq in overexpression 
studies.  Thus, it is unclear if endogenous effectors compete with each other, or if 
different effectors are sequestered via scaffolding with distinct receptors.  
Chemical inhibitors of specific effector interactions would help answer these and 
other questions about Gαq function in cells. 
 
In addition to PLCβ and p63RhoGEF, there is increasing evidence that GRK2 not 
only inactivates GPCRs, but also plays a role as a Gαq effector (Figure 17) (29).  
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GRK2 is well known for its role in phosphorylation independent attenuation of 
GPCR signaling by sequestering activated Gαq subunits (67-71).  The crystal 
structure of Gαq-GRK2-Gβγ (26) confirmed that GRK2 binds Gαq at the effector-
binding site.  Furthermore, as shown in Chapter 2, GRK2 and p63RhoGEF 
allosterically regulate Gαq-RGS interactions in a similar manner (130).  Thus, 
GRK2 is potentially a bona fide effector of Gαq.  However, the exact physiological 
significance of their interaction is not clear.  The obvious role of GRK2 is 
phosphorylation of GPCRs, and its association with Gαq may simply facilitate 
recruitment of GRK2 to the cell membrane, although such translocation has 
generally been attributed to Gβγ (122, 123). GRK2 has also been observed to 
phosphorylate non-receptor targets such as insulin receptor substrate 1 (IRS-1) 
(90), p38 MAP kinase (91), and ezrin (92) in response to activation of Gαq-
coupled receptors, consistent with the role of GRK2 as a signal transducing Gαq 
effector.  Thus, there is emerging evidence that GRK2 phosphorylates many 
other non-GPCR substrates, and associates with a variety of other proteins all 
involved in various signal transduction pathways (131).  Indeed, protein 
interactions surrounding GRK2 have become increasing complex granting GRK2 
its own “interactome” and implicating GRK2 in numerous pathologies (131).  
Small molecule inhibitors that could specifically inhibit the binding of Gαq to 
GRK2 would provide a powerful pharmacological tool for understanding the 




Protein-Protein Interaction Inhibitors 
Discovering small molecule inhibitors that disrupt protein-protein interactions 
(PPIs) is generally considered very challenging.  One of the major difficulties 
involved in targeting PPIs is the large contact surfaces involved (typically 1,500 – 
3,000 Å2) versus those in a protein-small molecule interactions (300-1,000 Å2) 
(132-134).  Additionally, the contact surfaces of PPIs are often flat and devoid of 
grooves and pockets that promote the favorable binding of small molecules.  
Furthermore, high-throughput screening (HTS) has a poor track record for 
discovering small molecule inhibitors of protein-protein interactions (135, 136).  
Despite these difficulties, major advances have been made towards discovering 
small molecule inhibitors of PPIs.  One of the first discoveries that opened up the 
idea was the identification of “hot spots” at protein-protein interfaces (137, 138).  
In “hot spots”, the majority of the binding energy of a PPI is contributed to a small 
subset of amino acids clustered at the center of the interface.  In principle, 
targeting these “hot” amino acids with small molecules would cause disruption of 
the entire interface (139).  For example, a “hot spot” on Gβγ was discovered by 
utilizing a peptide phage display library, which identified a peptide (SIRK) that 
bound near the center of the interaction surface for both Gα subunits and GRK2.  
A crystal structure between Gβγ and SIRK was then used as the basis for a 
virtual screen that ultimately indentified a set of compounds that could selectively 




Interaction of Gαq with GRK2 
The Gαq-GRK2 interface buries an accessible surface area of ~1700 Å2 (26), and 
mutational analysis has revealed several critical residues at the interface that are 
important for binding (26).  At the GRK2 interface, residues along the α5 helix of 
GRK2 dock into a small groove created between the α2-α3 helices of Gαq 
(Figure 18B,C).  Residues 261-263 of Gαq are important for the Gα specificity of 
GRK2 (26), but perhaps more importantly these residues bind in a small pocket 
at the GRK2 interface that could potentially be targeted with small molecule 
inhibitors and abrogate Gαq-GRK2 binding.  Furthermore, these residues have 
an accessible surface area of approximately 305 Å2, which is in line with surface 
area buried by small molecules.  Alternatively, we could identify small molecule 
inhibitors that bind elsewhere on the RH domain of GRK2 that change the 
interface allosterically.  It is known from our structures that the region of GRK2 
that binds Gαq is conformationally flexible, and thus could adapt to bind small 
molecules.  
 
Mutation of GRK2 residues Arg106, Phe109, Asp110, and Leu118 (Figure 18C, 
residues colored purple) abolish GRK2 binding to Gαq (27, 75) and contribute an 
accessible surface area of 364 Å2.  These critical residues not only bind in a 
hydrophobic pocket on Gαq, but also help in creating a shallow pocket on the 
surface of GRK2 where residues 261-263 of Gαq bind.  The surface area 
between residues 106-110 of GRK2 and 260-263 of Gαq form a potential “hot 
spot” that appears to be suitable for small molecule inhibitors.  It is certainly 
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reasonable that we may discover small molecules inhibitors that generically 
inhibit Gαq by binding into the groove of the effector-binding site.  However, such 
inhibitors are likely to be non-selective and may have limited use. 
 
 
Figure 18:  The Gαq-GRK2 interface.  A) Structure of activated Gαq binding to 
the RH domain of GRK2.  Gαq is colored slate, with the SwII helix colored red.  
Residues 97-141 of GRK2 are colored green.  B) A surface view of the GRK2 
interface.  Residues colored purple on the GRK2 interface are important for 
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binding to Gαq, while residues colored yellow on Gαq are important for binding to 
GRK2.  Switch II residues are also likely to be important for effector binding, 
however, mutation of these residues leads to a loss of function.  C) A surface 
view of Gαq with the α5-α6 helices of GRK2.  The α5 helix of GRK2 binds into a 
small groove on Gαq.  D) Analogous effector interaction with p63RhoGEF binding 
Gαq.  Residues colored white on p63RhoGEF are important for binding Gαq.  
Both p63RhoGEF and GRK2 utilize the same hydrophobic groove on Gαq for 
binding, thus inhibitors that bind Gαq are likely to be unselective. 
 
To our knowledge, there are no known small molecule PPI inhibitors (PPIIs) 
available for Gα/effector interactions (134).  However, Gαq is an established 
target.  A Gαq specific inhibitor, YM-254890, was discovered based on its ability 
to inhibit platelet aggregation (143).  YM-254890 is a cyclic depsipeptide that 
inhibits the GDP/GTP exchange on Gαq by inhibiting the release of GDP.  The 
crystal structure of YM-254890 bound to Gαqβγ revealed that the compound 
binds in a hydrophobic cleft (not the active-site) between the interdomain linkers 
connecting the GTPase and helical domains of Gαq (144).  YM-254890 has 
certainly proved valuable, given the increasing number of associated 
publications, but its functionality is limited since it blocks all downstream Gαq 
interactions.  We are thus primarily interested in small molecules that inhibit Gαq-
GRK2 by binding to GRK2.  Supporting this idea are several recently discovered 
PPIIs of the RGS4-Gαo interaction (102, 145-150).  Like GRK2, RGS4 has a 
structurally related RH domain, which binds Gα subunits.  Furthermore, one of 
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the RGS4 inhibitors was discovered by HTS using the flow cytometry protein 
interaction assay (FCPIA) (102, 151), an assay that has served as my workhorse 
for much of this thesis (130).  
 
Project Goals 
The importance of Gαq and GRK2 in regulating cardiovascular function is well 
documented.  Both proteins are implicated in the development of cardiac disease 
and hypertension.  Determining the specific role of the Gαq-GRK2 interaction 
may help us come to a complete understanding of cardiac physiology and 
disease, and may open up new avenues for therapeutic intervention.  Small 
molecule inhibitors that selectively inhibit this interaction would potentially serve 
as powerful pharmacological tools.  While the identification of PPIIs is a 
challenging goal, small molecules have been discovered that target both Gβγ 
subunits and RGS4.  Therefore, the identification of compounds that selectively 
target the Gαq-GRK2 interface should be feasible.  
 
METHODS 
Purification of Gαq 
A Gαi/q chimera containing the amino terminal helix (residues 1-28) of Gαi joined 
to the remainder of mouse Gαq (37-359) was purified as previously described 
(26), with one notable exception: Gαi/q was co-expressed with mammalian Ric-
8A.  Ric-8A is a non-receptor GEF (30, 152) for most Gα subunits (excluding 
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Gαs) and co-expression of Ric-8A with Gα subunits dramatically increases 
protein yields (Personal Communication, Gregory Tall).  Baculovirus for co-
expression of Ric-8A with Gαi/q was a gift from Stephen Sprang (University of 
Montana).   
 
Purification of GRK2 
GRK2-S670A was purified as described before (100).  The S670A mutation 
removes a MAP kinase phosphorylation site (153), which has no influence on in 
vitro kinase activity or Gαq binding. 
 
Preparation of Screening Reagents 
Alexa Fluor 488 labeling of Gαq 
Gαq was fluorescently labeled using the thiol-reactive probe Alexa Fluor 488 C5 
maleimide (AF-488; Invitrogen, #A-10254).  Before fluorescent labeling, Gαq was 
buffer exchanged into 20 mM HEPES pH = 8.0, 150 mM NaCl, and 50 µM GDP 
(no DTT) using a Micro Bio-Spin 6 chromatography column (BioRad).  A 3-fold 
molar excess of AF-488 was added to Gαq and allowed to react for 1 hour at 4°C 
in the dark.  The reaction was quenched by supplementing with 2 mM DTT, and 
the labeled protein was purified from excess fluorophore using a Micro Bio-Spin 6  
chromatography column.  Protein concentration was determined by 
spectrophotometric analysis (A280) correcting for AF-488.  Fluorescently labeled 




Biotinylation of GRK2 
GRK2 was biotinylated using a 3-fold molar excess of amine-reactive N-
hydroxysuccidimyl ester (Sigma, #H1759).  The reaction was incubated for 1 
hour at 4°C, and was quenched with 10-fold molar excess of glycine. Unbound 
biotin was removed using a Micro Bio-Spin 6 chromatography column, and the 
protein concentration was determined by A280.  Biotinylated GRK2 is henceforth 
referred to as bGRK2. 
 
Flow Cytometry Protein Interaction Assay 
Gαq-GRK2 Binding Assay 
Equilibrium binding experiments between Gαq and GRK2 were performed as 
previously described (130), with modifications.  Briefly, streptavidin polystyrene 
beads (2.0-2.9 µm; Spherotech, #SVP-20-5) were vortex mixed, and diluted into 
1 mL of –AMF buffer that contains: 50 mM HEPES pH=8.0, 100 mM NaCl, 0.1% 
lubrol, 5 mM MgCl2, 1% BSA, 2 mM DTT, and 50 µM GDP.  The beads were 
pelleted (2 min, 8K RPM), supernatant removed, and resuspended into 1 mL of –
AMF buffer a total of three times.  The beads were then resuspended into 500 µL 
of –AMF buffer, and bGRK2 was added such that its final concentration was 5 
nM.  The beads were incubated at room temperature for 30 min and 
subsequently washed three times.  Beads were then resuspended in –AMF 
buffer to their final assay volume (~5mL for one 96-well plate).  During the bead 
incubation, AF-Gαq was prepared.  Activation buffer (+AMF) for AF-Gαq was 
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prepared by adding 20 µM AlCl3 and 10 mM NaF (final concentrations) to –AMF 
buffer.  Concentrated AF-Gαq was diluted into both –AMF and +AMF buffers to 
achieve the inactive and activated states of Gαq, respectively.  AF-Gαq diluted in 
–AMF buffered served as our background control for the assay.  AF-Gαq was 
then serially diluted down a 96-well PCR plate to yield AF-Gαq concentrations 
generally between 0.78 and 100 nM.  Subsequently, 50 µL of bead bound 
bGRK2 was added to each well of the 96-well plate.  The proteins were 
incubated for ~30 minutes at room temperature in the dark before being read on 
Accuri C6 flow cytometer (Accuri Cytometers, Ann Arbor, MI) that was attached 
to a HyperCyt Autosampler (IntelliCyt, Albuquerque, NM).  Median fluorescence 
intensity was calculated and used for data analysis.  Data was fit to a one-site 
total and nonspecific-binding curve using Prism 5.0.   
 
Z-factor Determination 
Z-factor for our assay was determined using the following equation: 
 
 
where σ represents the standard deviation of the positive and negative (p, n) 
controls and µ represents the mean of the positive and negative control values.  
Positive controls were determined using 192-wells containing 5 nM of –AMF Gαq 
and negative controls were determined using 5 nM of +AMF Gαq.  In our system 
the positive controls represent full inhibition (0% bound) and the negative 
! 




controls represent no inhibition (100% bound).  Z-factors were determined in the 
presence of 1% DMSO to emulate screening conditions. 
 
Primary HTS Protocol 
The protocol for our primary screening assay was adapted from previous HTS 
campaigns that used FCPIA to screen for small molecule inhibitors against 
RGS4-Gαo (102, 151, 154).  Our screen was run in collaboration with the Center 
for Chemical Genomics (CCG) at the University of Michigan against ~40,000 
compounds from the following chemical collections: MS Spectrum 2000, 
ChemDiv, Maybridge HitFinder, CMLD, and the BioFocus NCC.  In brief, 0.2 µL 
of each compound was transferred into 10µL of bead bound bGRK2 using a 
Beckman BioMek XL liquid handling robot.  Next, 5µL of AF-Gαq in –AMF buffer 
was added to every well of a 384-well plate (Costar, #3676) for a final 
concentration of 5 nM AF-Gαq.  We subsequently added 5 µL of –AMF buffer to 
columns 23/24 and 5 µL of +AMF buffer to columns 1-22.  Plates were incubated 
at room temperature for 30 min, and then read on the Accuri-HyperCyt.  The final 
concentration of DMSO for the assay was 1% with a compound concentration of 
~10 µM.  Our assay format consisted of columns 1/2 as the negative control 
wells, columns 3-20 as the compound wells, and columns 23/24 as the positive 
control wells.  Data was binned and analyzed using HyperView software, and 
subsequently uploaded to the MScreen database.  The assay had a throughput 





Figure 19: HTS using FCPIA.  A) Schematic of the Gαq-GRK2 interaction using 
FCPIA.  Biotinylated GRK2 is immobilized on streptavidin beads.  Bead-bound 
fluorescence associated with AMF-activated Gαq binding GRK2 is measured via 
identification of the bead and the associated fluorescence of AF-488 using an 
Accuri C6 flow cytometer.  The binding affinity for activated Gαq-GRK2 is ~5 nM 
(see Chapter 2).  B) Schematic of the biotin/AF-Gαq counter-screen.  The 
biotin/AF-Gαq counter-screen was used to eliminate compounds that non-
specifically interact with the assay. 
 
Dose-Response Titrations and Counter-screening 
Dose-response titrations were run in parallel with a fluorescent counter-screen 
that consisted of biotinylated AF-Gαq (biotin/AF-Gαq) immobilized on streptavidin 
beads (Figure 19B).  Compounds were serially diluted by a factor of 3.16 in 10µL 
of +AMF buffer with a final concentration range of 100 µM to 31.6 nM.  
Biotinylated GRK2 (5 µL) and either AF-Gαq (5 µL) or biotin/AF-Gαq (5 µL) was 
subsequently added to each well, and bead-bound fluorescence was measured 




RESULTS AND DISCUSSION 
Development of a High-Throughput Screen for the Gαq-GRK2 Interaction 
FCPIA is readily adaptable for HTS.  We have previously used FCPIA to 
measure protein-protein interactions including the Gαq-GRK2 interaction 
(Chapter 2, (103, 112, 130)).  Prior to screening, instrumentation changes were 
made requiring the re-optimization of FCPIA.  Most notably, we switched to 
fluorescently labeling Gαq and biotinylating GRK2 (Figure 19A).  Binding of Gαq 
to GRK2 was retested under our new conditions yielding a Kd value of 6.6 ± 2.7 
nM (n=7, in duplicate) similar to our previously determined value of 3.2 ± 1.7 nM 
(Figure 20A). 
 
Figure 20: Assay development for HTS of Gαq-GRK2.  A) Direct binding of 
AF-Gαq to bGRK2.  The binding affinity of the AF-Gαq/bGRK2 interaction is 6.6 ± 
2.7 nM.  Data shown is mean ± SEM representative of 1 of 7 experiments in 
duplicate.  B) Z-factor determination for Gαq-GRK2.  AF-Gαq (5 nM) was added 
to bGRK2-bound beads.  The positive control consists of –AMF Gαq.  A Z-factor 
of 0.85 was calculated for the shown experiment.  The false positive hit rate of 
the assay is less than 0.1%.  
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To determine if our assay was suitable for HTS we determined a Z-factor over 
several experiments.  The Z-factor is a statistical parameter that is defined by the 
means and standard deviations of the positive and negative controls.  In practice, 
a Z-factor between 0.5 and 1.0 is desirable for screening (155).  We choose to 
use 5 nM AF-Gαq in our assay as it is reasonably close to its Kd value, increasing 
our chances of finding an inhibitor and allowing us to minimize consumption of 
the most expensive reagent. The calculated Z-factors for our assay were 
between 0.8 and 0.9 and tested over a period of up to 16 hours, over multiple 
protein batches (Figure 20B).  Overall, the high affinity of the Gαq-GRK2 
interaction in the presence of AlF4- and the low background fluorescence were 
very suitable for HTS. 
 
Primary Screening Results for Inhibitors against Gαq-GRK2 
We first performed a small pilot screen in the CCG against the MicroSource 
Spectrum 2000 compound library (MS2000), which includes FDA approved 
drugs.  Our Z-factor for the collection was ~0.85 over 7 plates with a signal-to-
noise of ~5.6.  A hit criteria of ≥15% inhibition per plate and a standard deviation 
per plate ≥ 3.0 resulted in 4 active compounds from the MS2000 library yielding 
an initial screening hit rate of 0.2%.  However, 3 of the 4 actives were 
immediately removed from follow up analysis, as one compound was highly 
promiscuous, and the other two compounds were biotin and gentian violet, which 
were of no further interest.  Based on the success of the pilot screen, we 
screened an additional ~38,000 compounds.  
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Data from the primary screen was triaged in collaboration with the Medicinal 
Chemistry Core Synthesis Lab (MCCSL) to select compounds for testing in dose-
response titrations.  The first criterion were compounds with a percent inhibition 
by plate greater than or equal to 15%, which resulted in 115 active compounds.  
The second criterion for actives was a standard deviation (calculated using 
negative controls and samples) by plate of greater than or equal to 3.  This 
criterion produced an additional 96 active compounds.  The last criterion used an 
activity cutoff for each plate that was defined as the negative control median 
value minus 6 times the standard deviation (calculated using only the negative 
control).  A compound was considered active if its value was than or equal to the 
activity cutoff.  This criterion resulted in an additional 32 active compounds. The 
active criteria produced a total of 243 active compounds, three of which were 
eliminated as described (from the MS2000 screen) yielding a primary screen hit 
rate of 0.6%.  
 
Elimination of False Positive Hits 
To cull out false positive hits, we tested our 240 active compounds 
simultaneously in dose-response titrations (Figure 21A) and in a fluorescence 
counter-screen (Figure 21B).   For the dose-response titrations we used an IC50 
value cut-off of less than or equal to 100 µM which produced 75 active 
compounds.  We then excluded compounds which had an IC50 value of less than 
or equal to 100 µM in the fluorescent counter-screen.  This resulted in 48 active 
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compounds, with 13 having an IC50 value between 1 and 10 µM, and the 
remaining compounds having an IC50 value over 10 µM.   
 
Figure 21: Dose-response titrations against Gαq-GRK2.  A) Example of two 
compounds with activity in dose-response titrations. CCG-17473 and CCG-
17656 both have an IC50 value of approximately 10 µM.  B) Fluorescent counter-
screen results for CCG-17473 and CCG-17656.  CCG-17473 is active against 
biotin/AF-Gαq and was removed from further analysis.  The results show mean ± 




Figure 22: Summary of active compounds from the Gαq-GRK2 screen.  
CCG-17853 is one of 12 other compounds that contain 8-hydroxyquinoline, a 
known high-affinity chelator of aluminum.  CCG-17473 was found to be active in 
the biotin/AF-Gαq counter-screen and was excluded from further analysis.  CCG-
42010 was tested in follow-up dose-response titrations using the CCG stock, 
however, its IC50 was well over 100 µm suggesting that it is an artifact.  CCG-
17656 was reordered, but failed to show activity in follow-up dose-response 
titrations.  CCG-18939 is active in follow-up dose-response titrations, but is a 
non-specific inhibitor likely due to its catechol group.   
 
We tested 10 of the 48 compounds in follow-up dose-response titrations, 
including CCG-17853, CCG-17656, and CCG-42010 (Figure 22).  Only CCG-
42010 had activity, but its IC50 value was over 100 µM suggesting that the 
compound is a non-specific inhibitor.  A substructure search revealed that 12 of 
the 48 compounds contain an 8-hydroxyquinoline group (Figure 22).  8-
hydroxylquinoline is well-known chelator of aluminum (156-159), and is likely 
inhibiting Gαq-GRK2 by removing aluminum, which is needed to form GDP·AlF4- 
and active Gαq.  Thus, the 8-hydroxyquinoline containing compounds (ex. CCG-
17853; Figure 22) were removed from further consideration. 
 
We ranked the remaining 34 active compounds by their potency and efficacy in 
dose-response titrations.  The efficacy of the majority of the compounds is very 
weak with an inhibition of less that 20% at 100 µM dose of compound.  As such, 
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we ordered our 10 best compounds from their respective vendors and retested 
them in dose-response titrations.  Only one of the reordered compounds, CCG-
18939, had activity in further dose-response titrations (Figure 23A).  CCG-18939 
also displayed similar activity against another Gα-effector interaction, Gα13-
LARG (Figure 23B).  Furthermore, CCG-18939 also had strong inhibition against 
RGS4 in a FRET assay, specifically on the donor fluorophore signal (data not 
shown, from Mscreen database).  Given these results, it is tempting to suspect 
that CCG-18939 is a non-selective Gα inhibitor.  However, CCG-18939 contains 
a catechol group, which is not only oxidizing and capable of changing colors and 
inhibiting fluorescence, but is also able of chelating aluminum ions (160).  CCG-
18939 is also active in a total of 8/56 CCG assays and when combined with its 




Figure 23:  Follow-up activity of our ten best hits.  A) Dose-response 
titrations against ten reordered CCG compounds.  Only CCG-18939 had activity 
below three standard deviations from the control (red line).  B) Dose-response 
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titrations of CCG-18939 against GRK2-Gαq, Gα13-LARG, and GRK2-C13.26.  
CCG-18939 has an IC50 value of ~75 µM against both GRK2-Gαq, and Gα13-
LARG.  The results show mean ± SEM run in duplicate. 
DISCUSSION 
PPIs play a key role in the regulation of almost every biological process.  As 
such, there has been much interest in inhibiting PPIs for their potential 
therapeutic value.  The prevailing view in literature indicates that targeting PPIs 
with small molecule inhibitors is a formidable challenge.  However, much 
progress has been made over the past 5 years in discovering small molecule 
inhibitors that specifically inhibit PPIs.  Many of the currently discovered small 
molecule inhibitors of PPIs come from interactions where the α-helix of one 
protein binds into a well-defined binding pocket of its partner protein (161), 
similar to the docking of the α5 helix of GRK2 into the Gαq effector binding site .  
Recent examples of successfully targeted protein/peptide-protein interactions 
include the JNK/JIP interaction (162), phospho-peptide/PLK-1 PBD interaction 
(163), the Calcineurin/NFAT interaction (164, 165), the SIGK/Gβγ interaction 
(140), and the p53/MDM2 interaction (166).  The majority of these interactions 
were screened against using a fluorescence polarization (FP) assay, however, 
FP requires the use of an isolated peptide-binding domain, which is currently 
lacking for the Gαq-GRK2 interaction.  Instead, we chose to use FCPIA to 
develop a high-throughput screen against the Gαq-GRK2 interaction.  FCPIA has 
been previously shown to be useful for studying PPIs, and has been previously 
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used as a screening platform to discover small molecule inhibitors of RGS 
proteins against Gαo (102, 151, 154). 
 
In our Gαq-GRK2 screen, we indentified 243 primary screen hits, which was 
narrowed down to 48 compounds after dose-response titrations and use of a 
fluorescent counter-screen (Figure 21B).  Out of the 48 compounds, 20 were 
tested for follow-up activity, with two compounds, CCG-42010 and CCG-18939 
having additional activity (Figure 22).  However, CCG-42010 has a relatively high 
IC50 value that is well over 100 µM.  Additionally, CCG-42010 has activity in 18 
out of the 44 primary screen assays run in the CCG, suggesting that this 
compound is a promiscuous inhibitor.  Our other identified compound, CCG-
18939, also suffers from a relatively high IC50 value of ~75 µM (Figure 23A).  
Furthermore, CCG-18939 inhibits both Gα13-LARG and Gαo-RGS4 (Figure 23B), 
and this could be a weak aluminum chelator due to its catechol group (160). 
 
Overall, our screening results failed to identify a small molecule inhibitor of Gαq-
GRK2.  We attribute the failure of the screen to the overall difficulty of inhibiting 
protein-protein interactions and not to poor assign design.  Current small 
molecule libraries are generally not designed towards inhibiting protein-protein 
interactions as they are come from compounds designed towards targeting 
enzyme active sites.  In fact, a majority of the currently described small molecule 
PPIIs have larger molecular weights (500-900 Da) than traditional small 
molecules (132).  To that extent we tried screening the Gαq-GRK2 interaction 
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against a collection of novel natural product extracts, however, the collection 
suffers heavily from artifacts when used in FCPIA.  
 
Our FCPIA HTS campaign routinely yielded Z-factors between 0.8-0.9 (Figure 
20B), indicating that our assay is well suited for HTS.  Our results do indicate, 
however, that FCPIA suffers from a relatively high false positive hit rate that 
could be due to several factors.  First, the assay is fluorescence based, and 
hence, will therefore suffer spectral artifacts that are common in many screening 
libraries.  However, spectral artifacts are easily eliminated by the use of a 
fluorescent counter-screen, such as biotin/AF-Gαq, and should therefore not be 
too concerning.  Another assay artifact we discovered is chelation of aluminum.  
FCPIA uses 20 µM AlCl3 in the assay buffer to form GDP·AlF4-, which activates 
Gαq and allows it to bind to GRK2.  We indentified a group of 12 compounds that 
contain 8-hydroxyquinoline, which is a chemical that can be used to chelate 
aluminum and measure its concentrations in water based on changes in its 
fluorescent spectra (156-159).  Therefore, these compounds are most likely 
inhibiting the Gαq-GRK2 interaction by deactiviating Gαq by removing the 
GDP·AlF4- complex.  
 
Another reason our false positive hit rate appears high is due to the triage criteria 
that we used to select compounds for dose-response titrations.  Overall, our HTS 
suffered from an overall lack of “hits”.  Only 7 compounds had a percent inhibition 
by plate of greater than or equal to 50%.  Comparatively, a similar assay (GRK2-
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aptamer, see Chapter 5) yielded 144 compounds with percent inhibition by plate 
of greater than or equal to 50%.  Thus, when we selected compounds for dose-
response titrations we were dipping into the noise of the assay and thereby 
increasing our false positive hit rate.   
 
Our initial search for discovering a small molecule inhibitor of Gαq-GRK2 failed 
with no discernable lead compounds to test in secondary assays.  While there 
appears to be a shallow pocket on GRK2 where residues 261-263 of Gαq bind 
(Figure 18B), it is still difficult to speculate if the surface of GRK2 can be targeted 
by small molecule inhibitors.  Recently, a small molecule inhibitor of RGS4 was 
discovered that is believed to target an allosteric site on the RGS domain (145).  
It is intriguing to speculate if GRK2-Gαq could be modulated by a similar 
interaction, but this would likely require screening against larger libraries and 
compounds more selectively engineered to the defeat of PPI’s, such as the 
natural products collections.  
 
FUTURE DIRECTIONS 
The Gαq-GRK2 interaction is certainly a novel interaction, and the discovery of a 
small molecule inhibitor of the interaction would not only serve as a useful 
pharmacological tool, but it would also support the protein-protein interaction 
inhibitor movement.  Our current HTS protocol is overall well suited for HTS, 
although, modifications to the assay could render the assay more useful by 
eliminating false positive hits due to aluminum chelation.  A “simple” change is to 
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remove aluminum from the assay, and use GTPγS or GMPPnP to active the Gα 
subunit. However, loading Gαq with GTP is generally more challenging than the 
other Gα subunits due to the slower rate of GDP release.  Our lab (and others) 
has been able to purify the non-receptor GEF Ric-8A and use Ric-8A to catalyze 
the exchange of GMPPnP onto Gαq.  This technique requires more protein, but 
given recent advances in our protein production capabilities and the fact the 
FCPIA uses so little protein, this is not a huge concern.  We have already shown 
that GMPPnP loaded Gαq is capable of binding GRK2 (Figure 24A) and it would 
be interesting to see what effect our aluminum chelator inhibitors have on this 
interaction. 
 
Figure 24: FCPIA with GMPPnP loaded Gαq.  A) GRK2 binding to 
Gαq(GMPPnP).  B) Loss of RGS4 binding affinity for Gαq(GMPPnP).  GMPPnP 
loaded Gαq could potentially eliminate many of the false positive hits seen in the 
Gαq-GRK2 screen. The results show mean ± SEM run in duplicate. 
 
Additional future directions could be aimed at generating small 3-4 amino acid 
peptides of either GRK2 or Gαq.  Such peptides could be used in an FP assay to 
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increase throughput over FCPIA and allow for screening at larger screening 
centers.  More importantly, if such peptides are able to inhibit the Gαq-GRK2 
interaction, they themselves could be used a starting point for a more rational 
design of small molecules that mimic the properties of the peptide (167). 
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Chapter 4  
Molecular Mechanism of Selectivity Among GRK2 Inhibitors 
 
BACKGROUND AND RESEARCH PLAN 
Dysregulation of kinase mediated signaling pathways results in a vast number of 
diseases including cancer, inflammation, diabetes, and heart failure, making 
them excellent targets for therapeutic intervention.  The kinase domain is 
composed of two lobes connected by a hinge region, with ATP binding between 
the two lobes (Figure 25).  There are several critical structural elements that 
cluster around the ATP binding sites of these kinases, including a phosphate-
binding loop (P-loop), an αC helix, a hinge loop, and an activation loop.  
Differences in these structures among the ~500 kinases in the human genome 
have generally been the focus for the rational design of selective kinase inhibitors 
and have underlain the molecular basis for selectivity exhibited by known 
inhibitors (168-172). 
 
Since the discovery of the linkage between the overexpression of GRK2 and 
heart failure, GRK2 has been considered a pharmaceutical target for the 
treatment of cardiovascular disease (see Chapter 5) (173).  Structural analysis of 
bovine GRK2 has led to several crystal structures including complexes with the 
heterotrimeric G proteins Gαq and Gβγ, and the non-selective AGC kinase 
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inhibitor balanol (Figure 26) (26, 174, 175).  Comparison of the ligand free GRK2 
structure with the balanol bound structure revealed that balanol stabilizes a 
slightly more closed conformation of the kinase domain (4° closure of large 
relative to small lobe).  However, an additional 16° rotation of the large lobe is 
still required to achieve the fully closed state, thus, balanol appears to stabilize a 
distinct inactive (open) conformation of GRK2 (175).    
 
 
Figure 25: Structure of the catalytic domain of GRK2.  The small (N-terminal) 
lobe (blue), consists of a β sheet, a phosphate binding loop (P-loop), and an αC 
helix that bears catalytic residues.  The large (C-terminal) lobe (green), is 
primarily helical and contains an activation loop that in most protein kinases is 
phosphorylated in order to achieve full activity (GRKs lack this phosphorylation 
site).  ATP binds between the two lobes, which are connected by a short hinge.  
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ATP is modeled from the crystal structure of the GRK1·ATP complex (PDB: 
3C4W). 
 
Recently, a class of heterocyclic compounds has been discovered by Takeda 
Pharmaceuticals (176) that both selectively inhibit GRK2 and show therapeutic 
potential (Figure 27).  In an effort to visualize GRK2 in a new, hopefully more 
active conformation, and to determine the mechanism of selectivity for these 
inhibitors, we proceeded to co-crystallize two of the discovered compounds 
(CMPDs 1/2, Figure 27) with the GRK2-Gβγ complex.  The solved crystal 
structures suggested that residues in the P-loop and αB-αC helices could 
contribute to compound selectivity.  Mutagenesis studies were performed to 
convert non-conserved residues around the inhibitor-binding site in an attempt to 
alter compound selectivity between GRK2 and GRK1, however with only modest 
success.  Therefore, the relative degree of kinase domain closure of GRK2 





Figure 26: Crystal structure of the hGRK2·balanol-Gβγ  complex.  Balanol 
bound to the ATP-binding site of human GRK2 (hGRK2) (PDB: 3KRW).  Balanol 
is drawn as a ball and stick model with carbons colored yellow, nitrogens blue, 
and oxygens red.  Conformational changes are observed in the P-loop and αB-





Figure 27: Small molecule inhibitors of GRK2.  The chemical structures of 
compounds (CMPD) 1, 2, and balanol.  CMPD’s 1/2 are potential cardiotonic 
drugs discovered by Takeda Pharmaceutical Company (176).  Balanol is a non-
specific AGC kinase inhibitor that is a natural product from the fungus Verticillium 
balanoides (177).  The ring structures are labeled as follows for CMPD’s 1/2: A = 
pyrimidine / pyridine, B = substituted 1,2,4-triazole, C = aminobenzamide, D = 
substituted benzene; for Balanol: A = p-hydroxybenzamide, B = azepane, C&D = 




Compound 1 (CMPD1), and compound 2 (CMPD2) were synthesized by an 
outside firm, and compounds were aliquoted and stored in 100% DMSO at -




Purification of GRK2 
GRK2 was expressed from a baculovirus vector containing the cDNA for bovine 
GRK2-S670A with an engineered C-terminal hexahistidine tag (178).  For protein 
expression, 25 mL of GRK2 baculovirus was added per 750 mL of High 5 cells at 
density of approximately 4x106 cells/mL.  The cells were harvested after 36-40 
hours and all purification steps were performed at 4 °C.  Cell pellets were thawed 
and resuspended in lysis buffer containing 20 mM HEPES pH 8.0, 50 mM NaCl, 
10 mM β-mercaptoethanol (βME), and protease inhibitors (1 mM PMSF, 1 µM 
leupeptin, and 1 mM lima bean trypsin inhibitor).  Cells were homogenized with a 
dounce and lysed using a C3 Avestin homogenizer (~10,000 psi).  The lysed 
cells were separated by ultracentrifugation using a Beckman Ti-45 rotor at 
45,000 rpm for 60 min.  The supernatant was collected, filtered, and diluted to a 
concentration of ~5 mg/mL in lysis buffer.  The filtered supernatant was then 
loaded onto a 10 mL nickel NTA column pre-equilibrated with lysis buffer.  The 
column was washed with 200 mL of lysis buffer, followed by 200 mL of lysis 
buffer supplemented with 150 mM NaCl and 20 mM imidazole.  The protein was 
then eluted with 100 mL lysis buffer plus 150 mM imidazole and collected in 
10 mL fractions.  Fractions containing protein were identified via mini-Bradford 
assay, pooled and then diluted 5-fold into 20 mM HEPES pH 8.0 and 2 mM 
dithiothreitol (DTT).  The diluted protein was filtered and loaded onto an 8 mL 
Source 15 S column (GE Healthcare).  Protein was eluted off with an 80 mL salt 
gradient from 0 to 500 mM NaCl and GRK2 containing fractions were confirmed 
via SDS-PAGE (Figure 28).  The protein was then concentrated with an Amicon 
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Ultra 50 kDa to a concentration of ~10 mg/mL.  The protein was then either 
frozen in liquid nitrogen for storage or loaded onto two tandem S200 gel-filtration 
columns (GE Healthcare) pre-equilibrated with 20 mM HEPES pH 8.0, 200 mM 
NaCl, and 2 mM DTT.  Peak fractions were analyzed by SDS-PAGE, pooled, and 
concentrated with an Amicon Ultra 50 kDa to ~10 mg/mL.  This protocol generally 
produced 10 mg of purified GRK2 from 6 L of culture. 
 
Figure 28: Purification of GRK2.  SDS-PAGE of GRK2 containing fractions 
eluted off an 8 mL Source 15S column (GE Healthcare).  Fractions 1D-11E were 
pooled and concentrated. 
 
Purification of Gβγ  
A pellet of cells expressing wild type Gβ1γ2-H6 (Gβγ) (harvested on 2-20-09) was 
provided by V. Tesmer.  Cells were resuspended in 200 mL of lysis buffer 
containg: 20 mM HEPES pH 8.0, 100 mM NaCl, 10 mM βME, 0.1 mM EDTA, and 
protease inhibitors (LL+PMSF).  Cells were homogenized with a dounce and lysis 
was performed by sonication.  The insoluble, membrane pellet was isolated via 
ultracentrifugation using a Ti 45 at 45,000 rpm for 1 hour, and then resuspended, 
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homogenized, and brought to a final volume of 400 mL with lysis buffer at a 
concentration of ~ 10 mg/mL.  Sodium cholate was added to 1% w/v and stirred 
in a beaker at 4 °C for 1 hour.  The supernatant was then isolated using a second 
ultracentrifugation step.  The supernatant was diluted into an equal volume of 
buffer (Buffer A) containing: 20 mM HEPES pH 8.0, 100 mM NaCl, 1 mM MgCl2, 
and 10 mM βME and then loaded onto a 5 mL nickel NTA column.  The nickel 
column was washed with 50 mL of buffer A containing 0.2% sodium cholate, and 
then washed with 100 mL of buffer A containing 300 mM NaCl, 10 mM imidazole, 
and 10 mM CHAPS.  The protein was eluted with 25 mL of buffer A containing 
10 mM CHAPS and 200 mM imidazole, and then diluted into 75 mL of buffer A 
containing 0 mM NaCl.  Protein was then filtered and loaded onto Mono Q 
column containing buffer A (with no salt).  Gβγ was eluted with a 20 mL salt 
gradient, and Gβγ-containing fractions (0.5 mL) were confirmed via SDS-PAGE 
(Figure 29A).  Gβγ was then pooled and concentrated with a Centricon 50 kDa to 
~10 mg/mL, and further purified over tandem S200 gel filtration columns and 




Figure 29: Purification of Gβγ . A) SDS-PAGE of Gβγ following separation by 
Mono Q anion exchange chromatography.  Fractions 28-40 were pooled.  B) 
SDS-PAGE of Gβγ fractions following gel filtration.  Fractions 9F-3H were pooled. 
 
Purification of the GRK2-Gβγ  Complex 
The GRK2-Gβγ complex was formed by mixing purified bovine GRK2-S670A 
(200 µL, 2.14 mg) with purified Gβγ (200 µL, 1.6 mg) and then supplementing 
with additional CHAPS and MgCl2 to final concentrations of 10 mM and 5 mM, 
respectively.  The protein mixture was incubated on ice for 30-60 minutes, and 
then filtered and loaded onto two tandem S200 gel filtration columns.  Formation 
of the complex was verified by SDS-PAGE (Figure 30), and the GRK2-Gβγ 
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containing fractions were pooled and concentrated (Amicon Ultra 50 kDa) to a 
final concentration of 13 mg/mL (100). 
 
Figure 30: Purification of the GRK2-Gβγ  complex.  A) Peak fractions 44-60 
and B) 61-76 from a GRK2-Gβγ gel filtration run.  Fractions #48-62 were pooled 
and concentrated to 13 mg/mL.  Fractions past 62 contained excess Gβγ and 
were not used.   
 
Crystallization of Ligand Bound GRK2-Gβγ  Complex 
Initially we attempted to co-crystallize GRK2 alone with CMPDs 1/2, however, 
those attempts yielded no crystal leads.  We then sought to co-crystallize 
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CMPD’s 1/2 with GRK2-Gβγ  using previously determined crystallization 
conditions for GRK2-Gβγ (179).  Initial trays were set up by adding either 100 µM 
CMPD1, 100 µM CMPD2, or 1 mM ATP to the concentrated GRK2-Gβγ complex 
on ice for 30 minutes.  Crystals were grown at 4°C by hanging drop vapor 
diffusion method initially with the protein mixed with the well solution at 1µL to 
1µL ratio, and were observable after 1 day (Figure 31).  Many different well 
conditions generated crystals such as: 100-200 mM NaCl, MES pH 5.6-6.7, and 
5-8% PEG 3350.  The best diffraction data for a GRK2·CMPD1-Gβγ crystal was 
harvested from a well solution containing 7% PEG3350, MES pH 6.25, 250 mM 
NaCl with drops composed of 2µL protein (10mg/mL protein) mixed with 2µL well 
solution.  Likewise, the best crystal for GRK2·CMPD2-Gβγ was harvested from 
7% PEG3350, 200 mM NaCl, and MES pH 5.25 with drops composed of 2 µL 
protein (10 mg/mL protein) mixed with 2 µL well solution.  For comparison, 
GRK2·ATP-Gβγ crystals were also generated using well solution with 9% PEG 
3350, 200 mM NaCl, and MES pH 6.5 with 1µL:1µL drops.  All crystals were 
harvested into a cryoprotectant solution containing: 20 mM HEPES pH 8.0, 
100 mM MES (at the well solution pH), 300 mm NaCl, 10 mM CHAPS, 5 mM 
MgCl2, 2 mM DTT, 9% PEG3350, 25% ethylene glycol, and either 100 µM 
CMPD1/2 (in 100% DMSO, final concentration 2% DMSO) or 1 mM ATP.  2% 
DMSO was added to the harvesting solution for the GRK2·ATP-Gβγ crystals so 




The inhibitor bound GRK2-Gβγ complexes crystallized in the space group C2 and 
diffracted anisotropically to spacings beyond 2.5 Å at APS beamline 21-ID-G.  
Overall, two complete data sets were collected for CMPD1, five for CMPD2, and 
two for ATP, and the data sets that produced the best omit maps with the highest 
redundancy were used for the structure determination.  The structures were 
solved using molecular replacement with the original GRK2-Gβγ structure (PDB: 
1OMW) (174) as the starting model (REFMAC5).  Models for the ligands were 
generated using Sketcher (CCP4 6.1) and PRODRG (180) 
(http://davapc1.bioch.dundee.ac.uk/prodrg/).  The ligand bound GRK2-Gβγ 
models were built using COOT (181), and refined using TLS and restrained 
refinement in REFMAC5 (182, 183).  MOLPROBITY (184) and PROCHECK 




Figure 31: Crystallization of GRK2·CMPD1/2-Gβγ . Crystals of (A) 
CMPD1•GRK2-Gβγ and (B) CMPD2•GRK2-Gβγ.  Crystals reached a maximum 
size of approximately 420 x 140 x 70 µm.  Both crystals belong to the space 




Production of GRK2, GRK1, and GRK5 Mutants 
GRK2 mutants were made using the QuickChange site-directed mutagenesis kit 
(Stratagene) to introduce mutations into the GRK2-H6 construct.  Mutants were 
expressed and purified as described for GRK2.  A baculovirus construct 
expressing bovine GRK1 with a C-terminal truncation at residue 535 and a 
hexahistidine tag (GRK1535-H6) was used to express GRK1 and the protein was 
purified as previously described (186).  GRK5 with a C-terminal truncation at 
residue 561 followed by a hexahistidine tag (GRK5561-H6) was expressed using a 
vector generated by Dr. Chih-chin Huang and purified similarly to GRK1535-H6 
(178). 
 
Rhodopsin Phosphorylation Assays 
Urea-washed bovine rod outer segments (bROS) were purified as previously 
described (187).  Steady-state kinetics were conducted using saturating 
concentrations of ATP (0.5 mM ATP + [γ32P-ATP]), 5-20 µM bROS, and 50 nM 
GRK in a buffer containing: 20 mM HEPES pH 8.0, 1 mM CHAPS, 5 mM MgCl2, 
and 2 mM DTT.  The reactions were carried out in a 96-well PCR plate.  For 
inhibition assays, 5 µL of varying concentrations of compound were added to 
each well, followed by addition of 5 µL GRK, and then 5 µL of bROS (added in 
the dark).  The plate was then allowed to equilibrate for at least 30 minutes.  The 
reaction was initiated by the addition of 5 µL of ATP and exposure to light at 
room temperature (~25°C).  The reaction was quenched after 5-10 minutes 
(within the linear range of enzyme activity, Figure 32) with the addition of 4 µL of 
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SDS-PAGE loading buffer.  Reactions were then analyzed by SDS-PAGE.  The 
gels were dried and exposed to a phosphor-imaging screen, and phosphorylated 
rhodopsin was quantified using a Typhoon 9410 imager (GE Healthcare).   
 
 
Figure 32: Linear kinetics of GRK2 activity.  Phosphorylation of bROS by 
GRK2 and the GRK2 mutants I197L, Y206S, and L235 over a time course of 15 
min.  Subsequent single time point phosphorylation assays were performed in 
the linear range of GRK2 activity (5 or 10 min time point).   
 
Enzyme activity was calculated as follows: for 500 µM ATP, the reactions contain 
500 pmoles of ATP per one µL.  One µL of reaction is diluted 1:1000 in assay 
buffer and one µL of the dilution is spotted onto the dried gels in multiple 
replicates (ATP-standard).   The ATP-standard is then calculated by dividing the 
amount of ATP (0.5 pmoles) by the averaged volume (from the phospho-imager).  
Sample reaction volumes are then multiplied by the ATP-standard to yield 
pmoles of Pi, which is then corrected by a dilution factor to yield total pmoles of 
Pi.  The total pmoles of Pi per sample is divided by reaction time (in minutes) and 
